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Abstract
Rheumatic heart disease (RHD) is the major cause of acquired heart disease and death for
children and young adults in developing countries. Poverty and social disadvantage are
thought to influence the clinical outcomes in RHD patients. Guided by the health lifestyle
theory, this study assessed the relationship between socioeconomic status and clinical
outcomes (heart failure events and mortality) in patients with RHD. It also examined how
adherence to penicillin prophylaxis mediates the effect of socioeconomic status (SES) on
clinical outcomes. Using the Nigerian database of the REMEDY study, this study was
conducted with 243 participants using Poisson regression and logistic regression models.
There was statistically significant association between SES and heart failure events
(OR=4.77, 95% CI=1.07-21.32, p=0.04). There was no significant association seen
between SES and mortality. Penicillin adherence was not a significant mediatory variable
in the relationship between SES and heart failure event and between SES and mortality.
These findings are consistent with studies showing low SES is a potential factor for
increased risk of recurrent heart failure events in RHD patients. It is however at variance
with studies that showed an increased risk of heart failure and mortality in patients with
poor adherence to penicillin prophylaxis. A positive social change implication might be
the need for physicians treating symptomatic patients with RHD to develop specific
strategies for patients from lower SES in order to reduce the recurrence of heart failure.
Future studies incorporating a composite measure of SES especially that using income as
proxy is needed to further improve our understanding of the role of SES in clinical
outcomes.
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Chapter 1: Introduction to the Study
Rheumatic heart disease (RHD) a chronic sequel of acute rheumatic fever is a
neglected public health problem prevalent among children and young adult in developing
countries including Nigeria (Watson et al., 2017). Global estimates suggest about 33.4
million people currently live with RHD with a further 400,000 new cases reported
annually (Watkins et al., 2017). In addition, about 319,400 individuals were estimated to
have died from RHD in 2015, while about 400,000 new cases were diagnosed annually
(Watson et al., 2017)
RHD is associated with huge public health burden especially in developing
countries (Watkins et al., 2017). Available reports show that it is the most common cause
of cardiovascular disease (CVD) in young people aged 25 years or below, the majority of
whom live in Africa, the South Pacific, Middle East, Central and South Asia with
associated high mortality and high disability-adjusted life years (DALYs). (Remenyi et
al., 2013; Watkins et al., 2016). Most children and young people with chronic RHD in
these developing countries present late or with severe disease needing surgical
intervention costing millions of dollars annually in health budgets (Watkins et al., 2017;
Zühlke et al., 2016). Current estimates suggest an annual spending in excess of 10 billion
dollars on surgical and other treatment for chronic RHD (Remenyi et al., 2013; Watkins
et al., 2016). Most of this spending occurs outside the country of origin of the affected
individuals leading to a needless capital flight (Remenyi et al., 2013; Watkins et al.,
2016). Surgery for RHD in most cases is palliative thus underscoring the need to increase
efforts at prevention initiatives especially benzathine penicillin secondary prophylaxis, a
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management tool demonstrated to improve clinical outcomes for patients with RHD
(Remenyi et al., 2013; Watkins et al., 2016).
In this chapter, I discuss the background of RHD and adherence to antibiotic
therapy and a gap in knowledge addressed. The research problem, study purpose, and
research questions are stated, and the theoretical basis for the study is introduced. In this
chapter, I also discuss the significance of this study, research design, assumptions, and
study limitations.
Background
RHD is a disease usually associated with social disadvantage that commonly
occur in children aged 5-15 years and young adults between the age of 20-30 years
(Carapetis & Zuhlke 2011). Poor hygiene, overcrowding, and poor ventilation
predisposes the individual to the acquisition of group A beta hemolytic streptococcal
(GABHS) pharyngitis, the original harbinger of acute rheumatic fever (ARF) which is the
precursor of RHD (Carapetis & Zuhlke 2011; Watkins et al., 2017). The 2017 global
burden of disease estimated age-standardized prevalence of rheumatic heart was 444
cases per 100,000 population for countries with an endemic pattern and 3.4 cases per
100,000 population for countries with a nonendemic pattern (Carapetis & Zuhlke 2011;
Watkins et al., 2017). From available reports globally, the average age at first diagnosis
of acute rheumatic fever occurs in children 10-14 years (Carapetis & Zuhlke 2011;
Watkins et al., 2017). In addition, death from RHD usually occurs in the second or third
decade of life. Seeing that death from RHD is uncommon among children between 5 and
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9 years of age, there could be a risk of serious underestimation of the endemicity of RHD
globally (Watkins et al., 2017).
Typically, RHD progression from initial insult of acute rheumatic fever to
symptomatic heart failure and in some cases death from the diseases and its related
complications may span a period of about 10 years (Watkins et al., 2017). Heart failure
is said to be the most common sequel of RHD with an estimate 295,300 cases (95%
uncertainty interval, 194,100 to 401,400) of mild heart failure, 243,700 cases (95%
uncertainty interval, 176,600 to 320,900) of moderate heart failure, and 663,000 cases
(95% uncertainty interval, 566,800 to 763,900) of severe heart failure, which represents
an 88% increase in the number of cases overall (Watkins et al., 2017).
Patterns of mortality due to rheumatic heart disease varied significantly according
to world health region in 2015 (Watkins et al., 2017). While global age-standardized
mortality from rheumatic heart disease decreased from 9.2 deaths per 100,000 population
(95% uncertainty interval, 8.7 to 9.7) in 1990 to 4.8 deaths per 100,000 population (95%
uncertainty interval, 4.4 to 5.1) in 2015, a decrease of 47.8% (95% uncertainty interval,
44.7 to 50.9), an estimated 77% and 82% of the deaths in 1990 and 2015, respectively,
occurred in countries such as India and sub-Saharan Africa where the diseases is endemic
(Watkins et al., 2017).
The goal for treatment of RHD is to prevent heart failure and recurrent ARF
where possible and allow for good clinical and functional outcomes for patients living
with this chronic disease (Remond et al., 2016; Yacoub et al., 2016). While surgical
management limits disability by improving cardiac function, it comes with the chronic

4
need for warfarin therapy and the need for INR measurement for life as a result of the
mechanical prosthesis inserted to replace the damaged heart valve (Cannon et al., 2017;
Watkins et al., 2017; Zühlke et al., 2016). Benzathine penicillin prophylaxis, a once
monthly or 3 weekly intramuscular injection has recently been shown to improve
outcome for RHD patients by reducing the frequency of ARF recurrences and heart
failure thus improving the overall outlook for the patient (Cannon et al., 2017; Watkins et
al., 2017; Zühlke et al., 2016). Since deaths from RHD is mainly from heart failure and
recurrent ARF, improve uptake of benzathine penicillin will in turn reduce the death rates
as such improve the clinical outcome for these patients living with RHD (Cannon et al.,
2017; Watkins et al., 2017; Zühlke et al., 2016). Seeing that SES disparities impact on
uptake of health interventions underscores the need for the measurement of disparities
and clinical outcomes in RHD management. Achieving the best possible outcomes for all
patients living with RHD would, therefore, include the measurement of outcomes by
SES. (Cannon et al., 2017; Watkins et al., 2017; Zühlke et al., 2016)
Problem Statement
Even though RHD is associated with social disadvantage as well as low
socioeconomic status, not many studies have looked at the role of SES in predicting
clinical outcome for patients with RHD (Watkins et al., 2017; Weinberg et al., 2016;
Zuhlke et al., 2016). In a multicenter study evaluating 3343 patients with RHD across 12
African countries, Zuhlke et al. (2016) found India and Yemen reported poorer outcome
for patients living in low income World Bank category countries. Patients from low
income countries had a mortality rate of 20.8% compared with those from the lower
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middle income and upper middle-income groups, who had a mortality rate of 16.55 and
12.5% respectively (p < 0.001) (Zühlke et al., 2016). In the same vein, new episodes of
congestive heart failure occurred in 9% of the patients from the low-income group
compared with those of the lower middle-income group and upper middle income who
had rates of 6.7% and 6.1% respectively (p = 0.006) (Zühlke et al., 2016). Similarly,
Okello et al. (2017) in a study of RHD patients in Uganda aged 5-60 years, reported a
mortality rate of 17.5%. Benzathine penicillin adherence rate less than 80% was noted in
that study to significantly increase mortality rates (31% vs 9%, log rank, p < 0.001)
(Okello et al., 2017). Antibiotic prophylaxis using penicillin has been demonstrated to
improve the outcome for people with RHD when started early in the course of the disease
(Remond et al., 2016; Yacoub et al., 2016). Complications like infective endocarditis,
atrial arrhythmias, incident heart failure, stroke and even deaths have been shown to be
more prevalent in children and young adults with severe RHD (Cannon et al., 2017;
Watkins et al., 2017; Zühlke et al., 2016). The success of the secondary prophylaxis is
thus hinged on the degree of adherence to the penicillin prophylaxis instituted (Cannon et
al., 2017; Yacoub et al., 2016; Zühlke et al., 2016). No study has evaluated outcomes or
role of BZP for patients with RHD in Nigeria even though RHD still remains a
significant health problem in Nigeria (Watkins et al., 2017).
In Africa, several factors have been associated with poor adherence to penicillin
secondary prophylaxis (Watkins et al., 2017; Zühlke et al., 2016). Poverty, illiteracy, and
access to care are some factors that have been implicated (Watkinset al., 2017; Yacoub et
al., 2016; Zühlke et al., 2016). However, not much is known about the influence of
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socioeconomic status and antibiotic adherence on the clinical outcomes of RHD (Cannon
et al., 2017; Yacoub et al., 2016; Zühlke et al., 2016).
Nature of the Study
This study utilized a retrospective cohort design to quantitatively analyze a
secondary data set of 243 Nigerian patients with RHD that were recruited and followed
up over a 2-year period as part of the rheumatic heart disease global registry (REMEDY)
study conducted across 12 African countries, Yemen and India (Karthikeyan et al., 2012;
Zuhlke et al., 2014). To address the question of the potential influence of SES on clinical
outcomes (heart failure and mortality rates) for these patients with RHD, this research
used a secondary data prospectively collected from a cohort of 243 RHD patients living
in 5 sites spread across the northern, central and southern parts of Nigeria. The patients
enrolled in that study were evaluated and managed according to standard practices
followed at each participating site using standard operating procedures domesticated at
each site (Karthikeyan et al., 2012; Zuhlke et al., 2014). The patients were enrolled from
5 sites spread across the north (Aminu Kano Teaching Hospital, Kano), central (Jos
University teaching Hospital, Jos and University of Abuja Teaching Hospital,
Gwagwalada) and southern parts of the country (University College Hospital, Ibadan and
Federal Medical Center, Abeokuta). Demographic data, clinical findings, and details of
electrocardiographic and echocardiographic findings on each patient were recorded in the
registry case report forms at research sites at baselines of 12 months and 24 months
(Karthikeyan et al., 2012; Zuhlke et al., 2014). This information was then transmitted and
stored at the University of Cape Town, Department of Medicine Project Coordinating
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Office (Karthikeyan et al., 2012; Zuhlke et al., 2014). The independent variable was SES
while the dependent variables were mortality and heart failure. Adherence to benzathine
penicillin was the mediator variable studied.
Purpose of the Study
The purpose of this study was to assess the relationship between individual level
SES and clinical outcomes (incident heart failure rate and mortality rate) in patients with
rheumatic heart disease (RHD). Secondly, it also examined how adherence to benzathine
penicillin prophylaxis mediates the effect of socioeconomic status on clinical outcomes
(heart failure and mortality rate) for these patients with RHD. The patients recruited
were categorized into two groups based on their SES as classified using the Oyedeji
system of SES classification (Oyedeji et al., 1985). One cohort (Cohort 1) contained
patients with low SES while the second (Cohort 2) contained patients with middle to
higher SES.
Socioeconomic status was the independent variable while clinical outcomes (heart
failure and mortality) were the dependent variables. Benzathine penicillin adherence was
the mediator variable.
Research Questions
Research Question 1 (RQ1). Does the number of heart failure events differ
between RHD patients of low SES and RHD patients of higher SES?
Null hypothesis (H01): There is no difference in number of heart failure events
between RHD patients of low SES and RHD patients of higher SES.
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Alternate hypothesis (Ha1): There is a difference in number of heart failure events
between RHD patients of low SES and RHD patients of higher SES.
Research Question 2 (RQ2): Does the mortality rates differ between RHD patients
of low SES and RHD patients of higher SES?
Null hypothesis (H02): There is no difference in mortality rates between RHD
patients of low SES and RHD patients of higher SES.
Alternate hypothesis (Ha2): There is a difference in mortality rates between RHD
patients of low SES and RHD patients of higher SES.
Research Question 3 (RQ3): Is there a significant difference in number of heart
failure events between RHD patients of low SES and RHD patients of Higher SES when
adjusting for the effect of benzathine penicillin prophylaxis adherence?
Null hypothesis (H03): There is no significant difference in number of heart
failure events between RHD patients of low SES and RHD patients of Higher SES after
adjusting for the effect of benzathine penicillin prophylaxis adherence rates.
Alternate hypothesis (Ha3): There is a significant difference in number of heart
failure events between RHD patients of low SES and RHD patients of Higher SES after
adjusting for the effect of benzathine penicillin prophylaxis adherence rates.
Research Question 4 (RQ4): Is there a significant difference in mortality rates
between RHD patients of low SES and RHD patients of Higher SES when adjusting for
the effect of benzathine penicillin prophylaxis adherence?
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Null hypothesis (H04): There is no significant difference in mortality rates
between RHD patients of low SES and RHD patients of Higher SES after adjusting for
the effect of benzathine penicillin prophylaxis adherence rates.
Alternate hypothesis (Ha4): There is a significant difference in mortality rates
between RHD patients of low SES and RHD patients of Higher SES after adjusting for
the effect of benzathine penicillin prophylaxis adherence rates.
Theoretical Basis of the Study
The conceptual model for this research was derived from the health lifestyle
framework, the theory, which was formulated by Cockerham in 2005 places emphasis on
how structural variables such as socioeconomic status, age, gender, and race/ethnicity,
social networks and living conditions provide the social context for socialization and
experience that ultimately determine lifestyle dispositions and practices (Cockerham
2005). This theory proposes that class circumstances SES may play an important role in
determining how individuals in a community make health decisions and choices
(Cockerham 2005). These choices may thus play an important role for both adherence
and clinical outcomes in patients with RHD (Cockerham 2005; Glanz, Rimer, & Lewis
2002). The correlation between SES and clinical outcomes has been previously
established for children with RHD (Okello et al., 2013; Zuhlke et al., 2014). Although a
correlation between SES and treatment adherence has been reported in several chronic
diseases such as asthma, this has not been conclusively established in RHD (Apter et al.
1998; Dean, Walters, & Hall 2010). The health lifestyle theory thus offered an
opportunity to understand how class circumstances such as socioeconomic status
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influences patients’ choices and decision (agency) on adhering to the monthly penicillin
injection (adherence) a health behavior necessary for improving the clinical outcome for
the particular patient (Cockerham 2005).
Operational Definitions
Acute rheumatic fever (ARF): an abnormal immune response leading to an
inflammatory disease that affects the endothelial lining of the joints, skin, brain and heart
following group A beta Hemolytic streptococcal pharyngitis.
Adherence to treatment regimen: Adherence refers to the extent to which an
individual’s behavior coincides with medical or health advice (Modi et al., 2012).
Congestive heart failure: Inability of the heart to pump blood to the body despite a
normal filling pressure.
Group A beta hemolytic streptococci (GABHS) pharyngitis: A bacterial infection
of the throat and surrounding tissues commonly seen in children aged 5-15 years and young
adults less than 30 years of age.
Mortality rate: Mortality is derived from the Latin word ‘mortalitas’ and refers to
the state of being subject to death. Mortality rate is thus a measure of the number of deaths
due to a specific cause in a particular population per unit of time (Gordis 2013).
Rheumatic heart disease (RHD): A chronic sequel of ARF that commonly involve
the mitral valvular structures with resulting incompetence and backward leakage of blood
into the left atrium.
Socioeconomic status: This is a complex concept that defines an individual’s
socioeconomic position in the society. Inherent in this concept is the reference to
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economic resources such as earnings, income, and wealth, social resources such as social
networks and connections to community resources, education and occupation. In the
context of this study, occupation and educational attainment were used as a proxy for
SES because of its intricate relationship to access to care and adherence to drug treatment
(Sewell & Velayos, 2013).
Assumptions
In this current study of SES, adherence behavior, and clinical outcomes (death or
mortality and heart failure events), my approach is formed by a postpositivist worldview
which posits that outcomes or effects are determined by causes (Creswel 2009). As a
result, being a reductionist, I assumed that concepts can be reduced to small, discrete sets
of testable ideas, and that empirical testing and measurement can inform our knowledge
of human behavior. Thus, the conceptual model chosen for this study places adherence to
benzathine penicillin secondary prophylaxis regimens in the pathway between SES and
Clinical outcomes (death, heart failure). According to the Health lifestyle theory, class
circumstances (SES) may play an important role in determining how individuals in a
community make health decisions and choices (Cockerham 2005). These choices may
thus play an important role for both adherence and clinical outcomes in patients with
RHD (Cockerham 2005; Cockerham 2013)
In this study, I assumed that SES leads to differences in clinical outcomes as
opposed to poor clinical status leading to differences in SES. I also assumed that patients
with greater disease severity or activity will more likely be adherent to BZP secondary
prophylaxis compared with patients whose disease is well controlled. Finally, I assumed

12
that low SES status negatively impacts adherence and poor adherence to BZP prophylaxis
will worsen clinical outcomes by increasing death rates and/or heart failure recurrences in
patients treated for RHD. These assumptions will be necessary to empirically test the
health lifestyle model of health disparities.
Scope and Delimitations
Socioeconomic disparities in RHD have been observed in both adult and pediatric
populations (Watkins et al., 2017). The scope of this study was limited to symptomatic
patients presenting in the hospital; asymptomatic patients identified through screening
were excluded. Adherence behaviors in symptomatic patients may be influenced by
disease severity, access to care and SES therefore, the results of this study may not be
applicable to asymptomatic RHD patients.
Limitations
I used secondary data from a disease registry to answer my research questions.
While disease registry provides a ready source of patient data for research, there are
inherent limitations to the use of this secondary source of data for research purposes (Yim
et al., 2017). First, the measurement of constructs is limited to data elements available in
the registry (e.g., a provider assessment of adherence to treatment regimen) and this may
affect the validity of the measures for adherence. This limitation was addressed in the
REMEDY study by using multiple sources of information (physician records and patient
monthly injection book records) in evaluating adherence to benzathine penicillin
secondary prophylaxis.
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Significance of the Study
The intent of this study was to bridge the gap in understanding the role of
individual level socioeconomic status on clinical outcomes for persons with rheumatic
heart disease. In addition, it was aimed at evaluating the possible mediatory role of
benzathine penicillin prophylaxis adherence on the relationship between SES and clinical
outcomes for these patients with RHD. The previously published report on this data had
demonstrated a significant relationship between country level socioeconomic status and
clinical outcomes in RHD patients (Zuhlke et al., 2015). Individual level SES was not
investigated (Zuhlke et al., 2015). Access to care and by extension drug adherence are
more readily affected by the individual’s economic status rather than the group economic
level (Yim et al., 2017). Since adherence is an individual health behavior (though
potentially influenced by group characteristics), it is easier to relate and thus examine the
effect of BZP adherence on health outcomes with individual level SES. The results of this
study add to the knowledge on the influence of socioeconomic status and adherence to
benzathine penicillin prophylaxis on clinical outcomes (heart failure and death) in
patients with RHD. It also adds to the knowledge on the mechanism through which
benzathine penicillin adherence, (a management tool shown to impact the course and
hence outcomes of RHD) mediate the relationship between socioeconomic status and
clinical outcomes in patients with RHD. The findings here will thus help to improve the
ways in which clinicians address the problem of benzathine penicillin secondary
prophylaxis for patients with RHD especially those whose adherence problem may stem
from poverty and its related factors thereby improving the clinical outcomes for them.
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Summary
RHD is the major cause of acquired heart disease and death from heart disease in
children and young adult in most parts of the developing world especially sub-Saharan
Africa. Currently, RHD has virally been eradicated in the developed countries such as the
US and UK except for occasional flares among immigrant populations.
Evidence shows that SES, adherence to drug therapy especially benzathine
penicillin secondary prophylaxis are important factors in determining outcome for
patients with RHD. The health lifestyle theory can potentially explain the role of SES
and adherence to benzathine penicillin secondary prophylaxis in determining outcome for
patients with RHD. There are currently no studies that evaluated the role of SES and
adherence to benzathine penicillin prophylaxis in patients with RHD using the health
lifestyle theory. This study was aimed at determining the relationship between SES and
clinical outcomes (heart failure and mortality) in patients with RHD and the role of
adherence to BZP as a mediator between the relationship of SES and clinical outcomes
(heart failure and mortality) in this population.
In Chapter 1, I provided the background of what is known about rheumatic heart
disease and its social determinants, the problem statement, the purpose of the study, the
different research questions and hypotheses, the theoretical framework of the study, the
nature of the study, the definitions, the assumptions, the scope and delimitations, the
limitations, and the significance.
In Chapter 2, I focus on discussion of literature in the area of socioeconomic
status and RHD. I provided a discussion of RHD and RHD risk factors and then
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subsequently provided a discussion of the theoretical framework, specifically studies that
used the health lifestyle theory to examine the relationship between SES and RHD as
well as the role of drug adherence on the relationship between SES and RHD. I then
concluded with a discussion of the relationship of the study to previous research.
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Chapter 2: Literature Review
SES is an important variable that predisposes to health disparities especially in
people living with chronic diseases (Claussen, 2015; Sliwa, Acquah, Gersh, & Mocumbi,
2016). Furthermore, people with low income or from low SES families have been shown
to be disproportionately burdened with higher morbidity and mortality from chronic
disease especially cardiac diseases compared with those from more advantaged
backgrounds (Hastert, Beresford, Sheppard, & White, 2015; Sommer et al., 2015; Wu,
Woo, & Zhang, 2013). SES disparities may affect a person’s access to health care, their
ability to pay for health services and possibly adherence to therapy all of which can have
important impact on the outcome for such chronic diseases (Claussen, 2015; Stringhini et
al., 2012, 2011). This study thus sought to assess the role of socioeconomic status on
clinical outcomes for patients with RHD. In addition, it examined how adherence to
benzathine penicillin prophylaxis treatment regimen mediates the effect of
socioeconomic status on clinical outcomes (heart failure and mortality) for these patients
with RHD. Exploring pathways between SES and clinical outcomes provides insight into
the way in which health disparities might occur in persons with RHD (Claussen, 2015;
De Dassel, Ralph, & Carapetis, 2015; Irlam, Mayosi, Engel, & Gaziano, 2013; Nulu,
Bukhman, & Kwan, 2017; Stringhini et al., 2012, 2011). This may help inform decisions
on developing framework for RHD control as well as policies and interventions that can
potentially eliminate these disparities and thence RHD (Irlam et al., 2013).
This literature review addressed the predictive relationship between individual
level SES and clinical outcomes in patients living with RHD. Major sections of the
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chapter include the literature search strategy, conceptual framework, and review of key
topics, including RHD epidemiology, pathogenesis, treatment patterns, prevention, SES,
and adherence to benzathine penicillin prophylaxis.
Literature Search Strategy
A systematic literature search was conducted using African Journal online
(AJOL), Cinahl, google scholar, Pubmed and Web of Science. In Pubmed, the following
medical subject headings (MESH) and free text terms were used: Rheumatic heart
disease” OR “Rheumatic valvular heart disease” OR “Rheumatic heart” OR “RHD”
AND “clinical outcome” OR “heart failure” OR “admissions” AND “Benzathine
adherence OR Compliance” OR “Secondary prophylaxis” OR “Penicillin adherence OR
compliance” OR “BZP”. The same text word search was used in Google scholar, AJOL,
CINAHL and Web of Science as in Pubmed. No search date limiter was used, however,
studies in the last 5 years were preferred. In addition, studies had to be peer reviewed to
be selected. Libraries were searched until March 2020. Studies were selected if they were
written in English, included human subjects, defined benzathine prophylaxis and
contained either rheumatic heart disease, or had clinical outcomes such as heart failure,
mortality or death. Any study that failed to define benzathine prophylaxis adherence rates
was excluded. A computerized bibliographical search was done that initially yielded
1,342 articles but 46 publications were eventually selected for inclusion in this review
because of their direct relevance to the study.
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Theoretical Foundation
The health lifestyle theory provided the foundation for this research work. The
theory was formulated by Cockerham in 2005 and later expanded in 2013 (Cockerham,
2005, 2013). Cockerham definesd health lifestyles as “collective patterns of healthrelated behavior based on choices from options available to people according to their life
chances” (Cockerham 2013). Cockerham’s health lifestyle theory was derived from
Bourdieu’s seminal work on lifestyles (Cockerham 2005, 2013). Bourdieu postulated that
lifestyle practices cluster in different strata of social space and that these different clusters
correlated with the different social classes found in the society(Cockerham, 2005, 2013).
According to Bourdieu, this class differences in lifestyles are hinged on the notion of
“distance from necessity.” The distance from necessity is thought to produces
dispositions to act (habitus), which generate practices (actions)(Bourdieu & de Saint
Martin, 1976; Cockerham, 2005, 2013). When these dispositions are acted upon they
result into the habitus that was the originator of the actions(Bourdieu & de Saint Martin,
1976; Cockerham, 2005, 2013). The theory thus posited that the further a person is from
the daily struggles for economic survival the more freedom and time such a person has to
develop and refine personal tastes typical of the higher social classes (“taste of
freedom”)(Bourdieu & de Saint Martin, 1976; Cockerham, 2005, 2013)i. In the same
vein, the closer a person is to the daily struggles for survival (lower social classes) the
less freedom and time such a person has to refine personal taste and thus adopt tastes
consistent with a life of daily economic struggle in which acquiring items of necessity is
critical (“taste of necessity”)(Bourdieu & de Saint Martin, 1976). Thus in this ensuing
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power struggle, the freedom from the daily necessities of life becomes the major
influence on decisions or actions taken by individuals(Bourdieu & de Saint Martin,
1976). Therefore, the distance from economic necessity leads to a class-based,
systematically unequal distribution of the instruments for appropriation of goods and thus
generates other such class-based inequalities(Bourdieu & de Saint Martin, 1976). In his
contribution to Bourdieu’s lifestyle theory, Cockerham expanded the meaning of
“lifestyle” to involve practices for maintaining health and preventing disease and not just
consumption practices(Bourdieu & de Saint Martin, 1976; Cockerham, 2005, 2013). In
his theoretical model, he conceptualized health lifestyles as consisting of a series of
personal routines that converged into an aggregate form representative of specific groups
and classes rather than a disjointed or uncoordinated behavior of disconnected individuals
(Cockerham 2005, p. 56). In other words, as is the case with general lifestyle practices
and tastes, health behaviors are correlated with socially determined structural variables
that exist outside of the individual, such as class circumstances, age, gender,
race/ethnicity, collectivities (religion, ideology), and living conditions(Bourdieu & de
Saint Martin, 1976; Cockerham, 2005, 2013). Of all these structural variables the class
circumstances, (socioeconomic class and the social and physical environments are the
main determinant that configures health behavior(Bourdieu & de Saint Martin, 1976;
Cockerham, 2005, 2013).
Previously, researchers have explored the role of SES as an independent variable
of interest in clinical outcomes for chronic diseases(Cockerham, 2014; Cockerham,
Hamby, & Oates, 2017). Recently, country level SES was a subject of study by Zuhlke
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and colleagues in their study of clinical outcomes for 3343 patients with RHD in 14
African countries, Yemen and India as an independent variable of interest in defining
clinical outcomes for persons with RHD (Zühlke et al., 2015). While country level SES
may be a marker of societal affluence, it is unlikely going to be a good surrogate for
individual level SES in predicting disease outcome which by all ramifications affects the
individual and is thus most likely be more predictive by individual level factors
(Claussen, 2015; Cockerham et al., 2017; Zühlke et al., 2015).
Health lifestyle theory is chosen for this study because of its applicability to
chronic diseases such as RHD (Claussen, 2015; Cockerham, 2014; Zühlke et al., 2015).
The health lifestyle theory postulates that the available life chances (structure) either act
to constrained or expand the possible choices or decisions (agency) a person makes
concerning their health (Cockerham, 2013). According to the health lifestyle theory,
people’s health lifestyle is shaped by the structural influences to which they are exposed
thereby limiting their choices to what is socially acceptable according to their
socioeconomic class (Cockerham, 2013). RHD is a chronic disease that begins in
childhood and if not appropriately treated continues into adult life (Cockerham, 2013;
Mayosi, 2014; Nulu et al., 2017; Shah et al., 2013). Low SES has several implications
for the patient with RHD as it impacts not just the development of the disease but also the
access to the necessary measures or treatment for the disease ( Liu, Lu, Sun, Zheng, &
Zhang, 2015a; Mayosi et al., 2014; Watson, Jallow, Le Doare, Pushparajah, & Anderson,
2015; L. Zühlke et al., 2015). In addition, RHD treatment relies on the patient’s
adherence to treatment regime for congestive cardiac failure as well as the 4 weekly
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benzathine penicillin injections for the prevention of ARF recurrence and thus the
progression of the RHD to severe disease and eventually death ( Liu et al., 2015a; Mayosi
et al., 2014; Watson et al., 2015; L. Zühlke et al., 2015). Thus, clinical outcomes for
patients with RHD will largely depend on class circumstances and the patient’s ability to
take action or decision about treatment regimens such as benzathine penicillin
prophylaxis variables to which the health lifestyle theory provides an appropriate
framework for asking research questions and predictive claims regarding SES and
adherence (Cockerham et al., 2017).
Adherence as a Health Behavior
Chronic diseases have become important cause of morbidity globally due to the
epidemiologic transition from infectious to non-infectious causes of disease(Harris, 2013;
Hruby & Hu, 2015). Since chronic diseases are not easily cured by medical treatment,
health lifestyle practices are becoming more important variables in determining clinical
outcomes for patients with chronic diseases(Benjamin et al., 2018; Ettehad et al., 2016;
Lyons, Lewis, Mayrsohn, & Rowland, 2014). As a result, patients with chronic diseases
have to make efforts daily working towards slowing down the disease process in order to
prevent premature death further underscoring the importance of life choices and by
extension health lifestyle in predicting clinical outcomes for patients with chronic
diseases(Benjamin et al., 2018; Ettehad et al., 2016; Lyons et al., 2014). This is seen in
the case of RHD patients whose treatment regime affects all aspects of their daily life(
Liu, Lu, Sun, Zheng, & Zhang, 2015b; Okello, Kakande, et al., 2017a). Applying
Cockerham’s health lifestyle theory to RHD care, I argue that adherence to treatment in

22
RHD is a health lifestyle practice adopted to minimize illness and maximize health as is
seen in other lifestyles practice like tobacco use, exercise, diet and utilization of
preventive health services such as immunization.
Conceptual Framework
The conceptual framework for this study was derived from the health lifestyle
theory which proposes that class circumstances (structure) play an important role both for
adherence (agency) and for clinical outcomes in persons with RHD (Cockerham, 2005,
2013; Cockerham et al., 2017; Goyal & Vijayvergiya, 2016; Mayosi, 2014). There have
been studies that established a correlation between SES and many chronic diseases such
as asthma, diabetes and coronary heart disease (Cockerham et al., 2017; Eisner et al.,
2011; Goyal & Vijayvergiya, 2016; Mayosi, 2014; Nandi, Glymour, & Subramanian,
2014; Pudrovska & Anikputa, 2014; Sommer et al., 2015; Wu et al., 2013). Although
recent studies have shown the important role of SES on the etiology and epidemiology of
RHD, not much has been done to evaluate the correlation of SES and clinical outcomes
for patients with RHD (De Dassel et al., 2015; Goyal & Vijayvergiya, 2016; Kumar &
Tandon, 2013; Mayosi et al., 2014; Stewart, Carrington, & Sliwa, 2016; L. Zühlke et al.,
2015; L. J. Zühlke & Karthikeyan, 2013). Similarly, little is known about the mediating
role of BZP adherence in the possible correlation between SES and clinical outcomes in
patients with RHD (Goyal & Vijayvergiya, 2016; Kevat, Reeves, Ruben, & Gunnarsson,
2017; Mayosi, 2014; Musoke et al., 2013; Okello et al., 2012; Okello, Longenecker,
Beaton, Kamya, & Lwabi, 2017; Kevat, Reeves, Ruben, & Gunnarsson, 2017; L. Zühlke
et al., 2015). In the light of this evidence and applying the framework of the health
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lifestyle theory, I argued that adherence to treatment contributes to the correlation
between SES and RHD clinical outcomes.
Rheumatic Heart Disease
Rheumatic heart disease, the chronic sequel of rheumatic fever is a disease
associated with social disadvantage and poverty (Cannon, Roberts, Milne, & Carapetis,
2017; Marijon, Mirabel, Celermajer, & Jouven, 2012; Nulu et al., 2017; Terreri & Len,
2016; L. J. Zühlke et al., 2017). It has persisted in the developing countries because of the
persistence of the social factors such as disorganized health system, poor housing,
overcrowding and widespread poverty the predisposing factors to the acquisition,
sustenance and persistence of the disease (Carapetis, Steer, Mulholland, & Weber, 2005;
Stewart et al., 2016; Wilson, 2010). It is a disease that results from poorly treated or
untreated group A beta hemolytic streptococcal pharyngitis especially in children
between the ages of 5 and 15 years of age (Carapetis et al., 2005; Karthikeyan &
Guilherme, 2018; Stewart et al., 2016; Wilson, 2010). Chronic RHD is associated with
huge financial burden on the families of affected children (Marijon et al., 2012; Zühlke &
Steer 2013; Zühlke et al., 2014). It renders a large proportion of children physically and
educationally handicapped and therefore deprive the country of potential skilled
workforce (Carapetis et al., 2005; Karthikeyan & Guilherme, 2018; Stewart et al., 2016;
Wilson, 2010). In addition, it put a strain on the already lean health budget of these poor
countries thereby further worsening already existing poor health indices in the population
(Marijon et al., 2012; Zühlke & Steer 2013; Zühlke et al., 2014).
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Epidemiology of Rheumatic Heart Disease
Rheumatic heart disease (RHD) is currently the most common acquired heart
disease in children and young adults living in the developing world especially those
living in sub Saharan Africa (Watkins et al., 2017). It used to be an important acquired
heart disease in the United States and United Kingdom in the early twentieth century but
with improvements in socioeconomic and living conditions, RHD completely
disappeared except for occasional flares among immigrant populations (Kočevar et al.,
2017). Current estimates suggest that about 33 million people are living with RHD
globally with a further estimated 280,000 new cases detected and a resultant 237,500
estimated deaths globally in 2016. About 70- 80% of these deaths are said to occur in
sub-Saharan Africa where poverty, malnutrition, poor hygiene and sanitation,
overcrowding and poor access to health all act together to sustain the burden of the
disease as well as the deaths occurring from the complications of the disease (Marijon et
al., 2012; Zühlke & Steer 2013; Zühlke et al., 2014). The persistence of these poverty
defining problems in sub Saharan Africa is what is currently responsible for the
persistence of RHD (Marijon et al., 2012; Zühlke & Steer 2013; Zühlke et al., 2014).
Aetiopathogenesis of RHD
RHD is a result of untreated or poorly treated group A beta hemolytic
streptococcal pharyngitis that culminates into acute rheumatic fever (ARF) which if left
untreated or become recurrent will eventually scar the endocardial lining of the heart and
thus by extension the valves and their apparatus (Carapetis et al., 2005; Karthikeyan &
Guilherme, 2018; Stewart et al., 2016; Wilson, 2010). This long term complication of
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ARF is what is referred to as RHD (Carapetis et al., 2005; Karthikeyan & Guilherme,
2018; Stewart et al., 2016; Wilson, 2010). Commonly, the initial streptococcal
pharyngitis and its ensuing sequel of ARF occur in childhood especially in those children
between 5 to 15 years.(Carapetis et al., 2005; Karthikeyan & Guilherme, 2018; Stewart et
al., 2016; Wilson, 2010) However, the majority of those who present with RHD
especially its severe form present in later childhood, adolescence and early adulthood
(Watkins et al., 2017).
RHD usually follows single or repeated episodes of ARF; an abnormal host
attempt at eradicating the causative agent group A beta hemolytic streptococcal
(GABHS) which cause pharyngitis (inflammation of the throat) (Karthikeyan &
Guilherme, 2018; Stewart et al., 2016). ARF occurs because of the similarity between
some parts of the GABHS bacterial cell wall and some parts of the host cardiac, brain,
skin and synovial tissues (Carapetis et al., 2005; Karthikeyan & Guilherme, 2018;
Stewart et al., 2016; Wilson, 2010). This abnormal host immune response is seen in only
about 0.3-3% of people who had the GABHS pharyngitis (Karthikeyan & Guilherme,
2018; Mayosi, 2014; Stewart et al., 2016). Repeated GABHS infection is thought to be
the initiating immunologic priming that predisposes to the development of ARF, the
precursor of RHD (Karthikeyan & Guilherme, 2018; Mayosi, 2014; Stewart et al., 2016).
This immunologic priming is also thought to be the main determinant of the age of onset
of ARF and thus RHD which commonly peaks at between 5 to 15 years (Karthikeyan &
Guilherme, 2018; Mayosi, 2014; Stewart et al., 2016).
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Predisposing Factors to RHD
RHD is a disease of poverty and social disadvantage hence its high burden in poor
countries especially those in Africa, India and south East Asia (Animasahun, Deborah,
Wobo, Itiola, & Oluwabukola, 2018; Watkins et al., 2017; L. J. Zühlke & Steer, 2013).
The factors that predisposed to and sustained it in these regions are deeply rooted in
poverty and social disadvantage (Animasahun et al., 2018; Watkins et al., 2017; L. J.
Zühlke & Steer, 2013). However, RHD can also be seen in rich countries such as
Australia where it is endemic among the indigenous or aboriginal populations as well as
the immigrant populations where social disadvantage is common (Animasahun et al.,
2018; Watkins et al., 2017; Zühlke & Steer, 2013). Malnutrition, overcrowding, poor
sanitation and hygiene and poor access to healthcare are all factors derived from poverty
that predisposed to and sustain the burden of ARF/RHD. Poverty is the single most
important risk factor associated with RHD (Kumar & Tandon, 2013; Marijon et al., 2012;
Watkins et al., 2017). Poverty breeds the social and environmental milieu that
predisposes, cause and sustained the scourge of RHD (Kumar & Tandon, 2013; Marijon
et al., 2012; Watkins et al., 2017). Conditions which promote high GABHS exposure are
usually set in socioeconomic deprivation (Terreri & Len, 2016; Zühlke et al., 2017).
Environmental factors. Overcrowding and poor sanitation are currently the most
significant determinant of the development of RHD (Okello et a., 2013;Terreri & Len,
2016; Zühlke et al., 2017). In a case control study involving 486 participants (243 cases
and 243 controls) in Uganda, Okello et al. (2013) reported an increased odd of having
RHD with increasing household overcrowding (OR-1.35; 95% CI= 1.1-1.56) (Okello et
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al., 2013). Jaine et al.,(2011) in an ecological study undertaken in New Zealand, showed
a significantly increased rate ratio of ARF cases associated with crowding quintile,
according to population-level data (Jaine, Baker & Venugopal 2011). Jaine et al.
reported rheumatic fever rate of 9.6 per 100,000 seen in the most crowded quintile was 4
times higher than the rate seen in the second most crowded quintile and 23 times more
than that of the quintile with the least household crowding compared to the quintile with
the least household crowding (Jaine et al., 2011). This effect remained even after
adjusting for age, ethnicity, household income, and the density of children in the
neighborhood suggesting. that household crowding is an independent factor associated
with rheumatic fever (Jaine et ali., 2011). This effect remained even after adjusting for
age, ethnicity, household income, and the density of children in the neighborhood
suggesting. that household crowding is an independent factor associated with rheumatic
fever (Jaine et al., 2011).
The association between overcrowding, GABHS infection, ARF and RHD has
been the subject of research over the past 50 decades(Karthikeyan & Guilherme, 2018;
Terreri & Len, 2016; Zühlke et al., 2017). Coffey, Ralph and Krause (2018) in a recent
systematic review of the social determinants of GABHS pharyngitis, ARF and RHD
examined 50 studies that reported on the association between household crowding and
the risk of developing ARF/RHD. A positive association between crowding and the risk
of developing ARF was found in 9 of 16 (56.3%) studies reviewed and RHD in 9 of 15
studies (60.0%). Coffey reported that only 14 of the 50 studies reviewed showed
consistent associations across all measures on the association between household
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crowding and the risk of developing ARF/RHD (Coffey, Ralph & Krause 2018). While
the quality of the studies may not be optimal, the evidence demonstrated in these
researches supports an association between crowding and ARF risk(Coffey, Ralph &
Krause 2018; Carapetis et al., 2005; Karthikeyan & Guilherme, 2018; Meira, Goulart,
Colosimo, & Mota, 2005; Terreri & Len, 2016; Zühlke et al., 2017). Overcrowding the
single most consistent factor in RHD epidemiology favors the spread of the GABHS
between individuals especially in the face of poor ventilation which further reinforce the
acquisition and spread of the organism(Islam & Majumder, 2016; Stewart et al., 2016;
Zühlke & Steer, 2013). This pattern is frequent seen among the urban poor where rapid
urbanization combine with poor housing to cause overcrowding and poor ventilation
thereby predisposing to ARF and thereafter its chronic sequel, RHD (Islam & Majumder,
2016; Stewart et al., 2016; Zühlke & Steer, 2013). The central role of overcrowding in
the aetiopathogenesis of RHD has also been demonstrated in contemporary studies
carried out in Australia and the developing world along with other societal markers of
poverty such as poor access to health care, low maternal literacy levels, unhygienic
environments and malnutrition (Islam & Majumder, 2016; Stewart et al., 2016; Watkins
et al., 2017; Zühlke & Steer, 2013). Poor people will most likely live in poorly ventilated
household with its attendant overcrowding and unhygienic surroundings breeding the
organisms that are the harbinger of streptococcal pharyngitis the precursor of ARF the
sequel of RHD (Islam & Majumder, 2016; Stewart et al., 2016; Watkins et al., 2017;
Zühlke & Steer, 2013).
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Malnutrition. Malnutrition is another poverty-related factor is an important
predisposing factor to ARF and also RHD that is associated with weakened or poor
immunity and thus an inability to naturally fight infectious diseases including GABHS
(Islam & Majumder, 2016; Stewart et al., 2016; Watkins et al., 2017; Zühlke & Steer,
2013). Potentially, childhood malnutrition has a link with increased susceptibility to
ARF/RHD probably due to the fact that malnutrition can increase susceptibility to
developing aggressive autoimmune responses to GABHS infection (Islam & Majumder,
2016; Stewart et al., 2016; Watkins et al., 2017; Zühlke & Steer, 2013). However, since
poor nutrition, household overcrowding and poor access to healthcare are associated with
poverty, it is possible that malnutrition may just be a surrogate for poverty as a cause of
ARF/RHD (Islam & Majumder, 2016; Stewart et al., 2016; Watkins et al., 2017; Zühlke
& Steer, 2013). Currently, there is no clear evidence linking malnutrition to GABHS
and/or ARF/RHD apart from its association with poverty (Zuhlke & Steer 2013).
Poor access to healthcare driven by poverty is another important predisposing factor to
ARF and RHD (Islam & Majumder, 2016; Stewart et al., 2016; Watkins et al., 2017;
Zühlke & Steer, 2013). An earlier study carried out by Gordis comparing outcome of care
for black children aged 5 to 14 years with RHD in Baltimore enrolled in a comprehensive
care program compared with similar aged matches group of RHD patient not enrolled in
the same care program reported a 60% drop in incidence of ARF in those enrolled in the
comprehensive care program (Gordis 1973). More recently, similar care programs
instituted in Cuba focusing on health literacy and health promotion towards attitudinal
change as well as improved access to BZP prophylaxis was shown to reduce the rates of
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ARF by more than 50% in the general population (Gordis 1973; Nordet et al., 2008).
While it is difficult to identify studies that directly assessed the impact of access to care
on the risk of ARF.RHD, these comprehensive care programs serve to demonstrate the
important role of access to care on the risk and burden of ARF/RHD in vulnerable
populations (Gordis 1973; Nordet et al., 2008). Poverty creates the structural factors that
makes many in developing countries to seek alternative care rather than present to
hospitals(Islam & Majumder, 2016; Stewart et al., 2016; Watkins et al., 2017; Zühlke &
Steer, 2013). This thus means that GABHS, a potentially treatable and curable infection
may be missed, poorly treated or not treated at all further predisposing the child or young
adult to the risk of ARF and thus RHD(Islam & Majumder, 2016; Stewart et al., 2016;
Watkins et al., 2017; Zühlke & Steer, 2013). Where this ARF becomes recurrent, further
damage is incurred on the heart with worsening of outcomes leading to frequent or
chronic heart failure potentially culminating in death(Cannon et al., 2017; Kumar &
Tandon, 2013; Mayosi et al., 2014; Shah et al., 2013; Zühlke et al., 2015).
Treatment Patterns for Rheumatic Heart Disease
Rheumatic heart disease being a chronic heart condition comes with a lot of
challenges for patients when we consider treatment options(Cannon et al., 2017; Nulu et
al., 2017; Zühlke et al., 2015). Access to appropriate intervention in an environment with
poorly developed health care infrastructure where RHD is endemic is crucial and may be
the missing link in appropriate and correct management of the disease in these patients
with established heart valve disease (Shah et al., 2013). For example, the REMEDY
study which evaluated 3343 RHD patients across 14 countries in Africa, India and
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Yemen showed that more than 50% of patients who are eligible for BZP secondary
prophylaxis, an effective tool for preventing worsening and recurrent ARF/RHD were not
receiving the therapy (Zuhlke et al., 2015). It is thus important that improved access to,
and affordability of, essential medicines such as benzathine penicillin, heart failure drugs,
and anticoagulants to prevent thromboembolic events be the main focus of policy makers
and clinicians alike (Regmi & Wyber, 2013; Shah et al., 2013; L. Zühlke et al., 2015).
Rheumatic heart disease being a valvular heart disease is associated with
mechanical disturbances of cardiac valve function especially the mitral valve which
commonly presents with mitral incompetence leading to regurgitation and back flow of
blood thus predisposing to frequent heart failure in those affected (Carapetis, Brown,
Maguire, & Walsh, 2012; Regmi & Wyber, 2013; Boglarka Remenyi, Elguindy, Smith,
Yacoub, & Holmes, 2016; Shah et al., 2013; Smith, Zurynski, Lester-Smith, Elliott, &
Carapetis, 2012; Zühlke et al., 2015). Heart failure is the most frequent complication seen
in about 30 percent of new patients seen with RHD (Carapetis et al., 2012; M. Liu et al.,
2015b; Mehta et al., 2016; Regmi & Wyber, 2013; Boglarka Remenyi et al., 2016; Shah
et al., 2013; Smith et al., 2012; L. Zühlke et al., 2015). In addition, it is the most frequent
cause of death in those affected with RHD with about 17% dying within 2 years of
enrolment in a follow up care program especially when the disease occurs early in
childhood (Carapetis et al., 2012; Smith et al., 2012; Zuhlke et al., 2015). Heart failure
management with diuretics is the main stay of treatment for most patients with
symptomatic RHD especially those with chronic heart failure (Carapetis et al., 2012;
Smith et al., 2012). The availability of potent diuretics especially the loop diuretics has
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helped to improve the control of heart failure in these patients with RHD thus reducing
the rate of death associated with heart failure in these patients (Nieuwlaat et al., 2014;
Nulu et al., 2017; Shah et al., 2013).
Prevention Strategy for Rheumatic Heart Disease
Rheumatic heart disease is wholly preventable using simple, basic, cost effective
public health measures such as improvement in living conditions and nutrition
rehabilitation (Irlam et al., 2013; Gordis 1973;Nieuwlaat et al., 2014; Nulu et al., 2017;
Regmi & Wyber, 2013; Remenyi, Carapetis, Wyber, Taubert, & Mayosi, 2013; Shah et
al., 2013). Evidence from the United States suggest that improvements in living
conditions, sanitation and poverty reduction was responsible for the greater than 70%
drop in cases of ARF/RHD seen in the 20th century (Irlam et al., 2013; Gordis
1973;Nieuwlaat et al., 2014; Nulu et al., 2017; Regmi & Wyber, 2013; Remenyi et al.,
2013).Its persistence in the developing countries especially Sub Saharan Africa
exemplifies the failure of coordinated efforts of public health practitioners, policy makers
and implementers (Gordis 1973; Nulu et al., 2017; Remenyi et al., 2013). Such
prevention efforts must be targeted at the social determinants of the disease as well as the
improvement of access to care for streptococcal pharyngitis as well as those who develop
the disease (Irlam et al., 2013; Nordet et al., 2008; Remenyi et al., 2013; Zühlke &
Karthikeyan, 2013). These measures are needed in order for meaningful progress to be
made at the control and prevention of the disease (Remenyi et al., 2013). Such prevention
and control measures for RHD must be targeted at the reduction of household crowding,
timely diagnosis and appropriate antibiotics for bacterial pharyngitis and – in people who
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develop rheumatic fever – antibiotic prophylaxis over several years to prevent disease
progression (Irlam et al., 2013; Irlam, Mayosi, Engel, & Gaziano, 2013; Remenyi et al.,
2013).
Role of School based Echocardiography screening in the Prevention of RHD
Community based echocardiographic screening especially in school children who
happen to bear the brunt of the disease is said to increase the detection rates for RHD by
about 10-15 times when compared with cardiac auscultation and thus proved to be an
important tool for the detection of asymptomatic RHD (Beaton et al., 2012; Irlam et al.,
2013; Irlam et al., 2013; Remenyi et al., 2013; Rothenbühler et al., 2014; Shah et al.,
2013). Early detection of RHD especially in those who are yet to show signs of the
disease opens the way for early initiation of BZP prophylaxis for the prevention of
GABHS episodes and as such recurrence of ARF (Beaton et al., 2012; Irlam et al., 2013;
Irlam et al., 2013; Remenyi et al., 2013; Rothenbühler et al., 2014; Shah et al., 2013).
Echocardiographic screening for RHD in school children has been demonstrated to
increase the uptake of BZP prophylaxis by about 40% and thus helped reduce the onset of
severe disease and other complications associated with RHD (Cannon et al., 2017;
Mason, Retzer, Hill, Lincoln, & Centers for Disease Control and Prevention (CDC),
2015; Rothenbühler et al., 2014). In Fiji, Engelman reported that overall admission rates
in clinically diagnosed RHD in symptomatic children is 4 times higher compared with
that of echocardiography-based screening detected asymptomatic children. (RR 4.3, 95%
CI 2.8–6.8) (Engelman et al., 2017). In addition, RHD-related admissions bed days were
higher in the clinically diagnosed group compared with the echocardiography-based
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screening-detected group (IRR 6.6, 95% CI 5.6–7.8) (Engelman et al., 2017).
Echocardiography based school screening is thus significantly associated with reduced
morbidity and mortality(Engelman et al., 2017). A similar effort in Australia has
demonstrated the same results for aboriginal children who bear the brunt of the disease in
Australia (Carapetis et al., 2012; Parks, Smeesters, & Steer, 2012; Steer & Carapetis,
2009). The advent of echocardiography has thus helped in no small measure towards not
just making an early diagnosis but also in the prevention and control of RHD globally
(Carapetis et al., 2012; Marijon, Celermajer, & Jouven, 2017; Parks et al., 2012;
Rothenbühler et al., 2014; Steer & Carapetis, 2009).
Penicillin Secondary Prophylaxis
In a classic study suing a cohort design, Stollerman, Russoff and Hirschfeld
(1955) showed that secondary prophylaxis using 4 weekly 1.2 mega units intramuscular
BZP was successful in preventing ARF recurrence in patients followed up for 20 months
(Stollerman, Russoff & Hirschfeld 1955). In their report, none of the patients on BZP
developed ARF compared with their counterparts on oral penicillin or sulfadiazine
(Stollerman et al., 1955). Adequate Penicillin prophylaxis described as at least 80% of the
prescribed annual dose improved outcomes and reduces the risk of death especially where
access to healthcare is limited (Nordet et al., 2008; Nulu et al., 2017). Recently, de Dassel
et al., in a review of register data of Australian patients with RHD reported a 4-fold
increase in the odds of having ARF in patients who had suboptimal (<80% of annual
doses) adherence to BZP (de Dassel et al., 2018). Intramuscular benzathine penicillin
(BZP) injections serve as the main prophylaxis and a key component of RHD control
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programs (Irlam et al., 2013; Manji et al., 2013; Regmi & Wyber, 2013; Remenyi et al.,
2013; Smith et al., 2012; Watson et al., 2015; Zühlke et al., 2017). This approach is
aimed at preventing group A beta-hemolytic streptococci (GABHS) streptococcal
infections the harbinger of ARF and by extension subsequent recurrent episodes of ARF
the precursor of RHD ( Irlam et al., 2013; Nulu et al., 2017). Current recommendations
by the World Health Organization (WHO) stipulates a 3-4 weekly BZP injection for a
duration dependent on factors including age, time since the last episode of ARF, risk of
streptococcal infections in the area and presence of RHD (Rémond, Coyle, Mills, &
Maguire, 2016a). Based on the WHO guidelines, secondary prophylaxis is advised for at
least 5 years after the last episode of ARF or until the age of 18 years (whichever is
longer) and for a greater length of time for persons who had cardiac involvement at the
initial episode of ARF or in those with established RHD (Remenyi et al., 2013; Rémond
et al., 2016a).
For a successful RHD prevention, a well-coordinated BZP prophylaxis hinged on
good drug supply chain and easily accessible centers for BZP injection is key (Nieuwlaat
et al., 2014; Watson et al., 2015; Zühlke & Karthikeyan, 2013). In the more than 50 years
of using penicillin in the treatment of GABHS pharyngitis associated with ARF/RHD,
antibiotic resistance has not been reported against penicillin G and its generics (Kumar &
Tandon, 2013; Liu et al., 2015a). This has made penicillin G an excellent and yet useful
tool for the much needed RHD control program globally (Kumar & Tandon, 2013; Liu et
al., 2015a). While concerns about penicillin allergy and the pains of intramuscular
injections have been the main hindrances to the widespread uptake of BZP prophylaxis in
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RHD endemic areas, current evidence suggest a low or near absent presence of serious
anaphylactic reactions to penicillin (Kumar & Tandon, 2013; Liu et al., 2015a).
Clinical Outcomes in RHD
RHD a disease of children and young adults is associated with many
complications(Kumar & Tandon, 2013; Liu et al., 2015a; Stewart et al., 2016; Watkins et
al., 2017). Patients with RHD are at an increased risk for congestive heart failure,
arrhythmias, stroke and infective endocarditis( Liu et al., 2015a; Zühlke et al., 2015). The
REMEDY study, a 2 year prospective study which contains the largest contemporary data
on the outcomes of clinically diagnosed RHD from multiple centers across 12 different
African countries, Yemen and India reported congestive cardiac failure in 20% of the
patients seen at baseline (Zühlke et al., 2015). In addition, a high mortality rate was noted
especially in those who had severe disease, heart failure or were older than 20 years at the
time of being recruited into the study (Zühlke et al., 2015). A similar study conducted in
Fiji though using a younger cohort of patients reported similar outcomes to that seen in
the REMEDY study though with a higher mortality rate (Engelman et al., 2017). Severe
disease and a frequent occurrence of heart failure are key predictors of death for patients
with RHD as seen in both the REMEDY and the Fiji study (Engelman et al., 2017;
Zühlke et al., 2015).
Disease severity at diagnosis has been consistently shown to be a major predictor
of clinical outcome for patients with RHD ( Liu et al., 2010; Nulu et al., 2017; Okello,
Kakande, et al., 2017a; Zühlke et al., 2015). In Australia, Cannon et al., using RHD
register information on 591 Indigenous residents diagnosed with RHD in the Northern
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Territory between the ages of 5 and 24 years over a 14 year period observed that 30% of
the patients had severe disease at baseline (Cannon et al., 2017). For these patients with
severe disease, Cannon et al., reported a 5 year mortality rate of 10% compared no deaths
in those who presented with mild RHD at diagnosis (Cannon et al., 2017). Despite this
favorable mortality rate, 11.4% of those who presented with mild RHD still progressed to
severe RHD within a 10 year period with half of them requiring valvular surgery(Cannon
et al., 2017).
Even though there is no conclusive evidence for a gender predilection in the
etiology of RHD, women and girls have been shown to be disproportionately affected
with RHD(Watkins et al., 2017; Zühlke et al., 2015). Women living with RHD and who
get pregnant are also prone to pregnancy related complications such as heart failure,
premature delivery, fetal death and even maternal death(Watkins et al., 2017; Zühlke et
al., 2015). However, gender on its own has not being shown to be an independent
predictor of death or progression of disease in patients with RHD (Liu et al., 2010).
Socioeconomic Status and Clinical Outcomes in RHD
Clinical outcomes for chronic diseases have been shown to be worst as one goes
down the socioeconomic quintiles(Cannon et al., 2017; Centers for Disease Control and
Prevention, 2018; Zühlke et al., 2015). Chronic diseases such as cystic fibrosis have been
demonstrated to be associated with worst outcomes especially death in patients who are
poor and uneducated (Oates et al., 2016). The socioeconomic gradient in clinical
outcomes for heart related disorders such as myocardial infarction was shown to be
associated with the increased in the modifiable risk factors for cardiovascular disease
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such as hypertension, dyslipidemia and tobacco smoking and not so much because of the
low socioeconomic status of the patients (Choudhry et al., 2014). This however has not
been conclusively demonstrated in RHD. While the REMEDY study showed a higher
mortality rate as well as incident heart failure rates in patients from low income and low
middle income countries, causality cannot be established because of the ecological theory
fallacy (Zühlke et al., 2015).
Socioeconomic Status and Benzathine Penicillin Adherence in RHD
A relationship between socioeconomic status and adherence in RHD has not been
conclusively determined (Goyal & Vijayvergiya, 2016; Watson et al., 2015; Zühlke et al.,
2015). A person’s SES is said to affect their ability to access and utilize health
information and services (Cockerham et al., 2017; Eisner et al., 2011; Goyal &
Vijayvergiya, 2016; Watson et al., 2015; Zühlke et al., 2015). Low health literacy as well
as absence of any formal education has been shown to predispose to poor adherence to
penicillin prophylaxis in patients with RHD living in low and lower middle income
countries (Ralph. et al., 2016; Huck et al., 2015; Rémond et al., 2016). While no causal
link has been established between RHD adherence rates and socioeconomic status of the
individual patient, unemployment, a surrogate for SES was shown to be associated with
poor adherence to BZP prophylaxis in Uganda (Longenecker et al., 2016). In India, a
cross sectional evaluation of 500 patients with RHD on BZP prophylaxis reported a high
rate of poor adherence to BZP prophylaxis (Shah et al., 2013). Low SES, being
uneducated and residing in a rural area was found to be significant determinants of poor
access to BZP prophylaxis (Shah et al., 2013). In their prospective study of 449 Ugandan
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patients with RHD, Okello et al. reported that poor adherence to BZP prophylaxis or
suboptimal adherence to benzathine penicillin injections (BZP injections less than 80% of
total annual injections) was associated with a high rate of incident heart failure and
mortality (Okello, Kakande, et al., 2017a). Heart failure and also mortality was directly
correlated with the rate of progression from mild to severe disease (Okello, Kakande, et
al., 2017a).
Adherence and Clinical Outcomes in RHD
Adherence in RHD has been variously defined depending on the study design and
end point( Islam & Majumder 2016; Kevat et al., 2017; Lam & Fresco, 2015). However,
adherence defined on the basis of the proportion of BZP injections received as a fraction
of expected total annual injections has recently been widely used in estimating adherence
rates(Okello, Kakande, et al., 2017b). An adherence rate of at least 80% is currently the
most widely accepted cut off point for optimal or adequate adherence rates for BZP
prophylaxis in RHD(Okello, Kakande, et al., 2017b). Longitudinal studies on adherence
to BZP prophylaxis has been shown to be associated with an improved outcome for
patients diagnosed with RHD especially those with mild disease(Mehta et al., 2016;
Okello, Kakande, et al., 2017b). Adequate adherence successfully reduce the rate of ARF
recurrences and hence the progression and severity of RHD in patients already living
with RHD (Chamberlain-Salaun, Mills, Kevat, Rémond, & Maguire, 2016; Mehta et al.,
2016; Okello, Kakande, et al., 2017b; Rémond et al., 2016a).
Adherence as the Mediating Pathway between SES and Clinical Outcomes in RHD
There are currently no studies that evaluated the mediatory role of benzathine penicillin
adherence on the relationship between SES and clinical outcomes in patients with RHD
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(Huck et al., 2015; Kevat et al., 2017; Okello, Kakande, et al., 2017b; Ralph et al., 2016).
However, the role of medication adherence linked with SES on health outcomes had been
studied in other chronic disease conditions such as HIV, asthma, diabetes and
hypertension(Burch et al., 2016;Huck et al., 2015; Nandi et al., 2014; Oates, Britton,
Gamble, & Harris, 2015; Okello, Kakande, et al., 2017b; Ralph et al., 2016; Wayda et al.,
2018). In one such study, Burch et al., assessing the effect of socioeconomic status
(financial hardship, non-employment, rented or unstable housing status, and nonuniversity education) on virologic outcomes in people receiving antiretroviral treatment
(ART) for HIV in the UK, reported a strong association between lower socioeconomic
status with ART non-adherence and virologic non-suppression on ART(financial
hardship vs none 2·4, 95% CI 1·6–3·4; non-employment 2·0, 1·5–2·6; unstable
housing vs homeowner 3·0, 1·9–4·6; non-university education 1·6, 1·2–2·2) (Burch et
al., 2016). When they adjusted for adherence to ART in their logistic model, there was a
weakening in the association between SES and virologic outcomes further suggesting that
the associations between low socioeconomic status and virologic non-suppression are
probably mediated mainly through ART non-adherence (Burch et al., 2016).
While ART drugs may differ significantly from BZP in being oral medications
rather than intramuscular injection, the findings by Burch et al., still underscores a need
for more research on adherence to BZP prophylaxis as a potential mediator of the
relationship between SES and clinical outcomes in patients with RHD(Burch et al.,
2016). This is even made more plausible because of the dearth of information in the
literature on adherence as a potential mechanism of socioeconomic disparities in clinical
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outcomes for RHD patients (Goyal & Vijayvergiya, 2016; Oates et al., 2016). Most
studies of adherence in RHD use cross-sectional research designs that limit conclusions
regarding potential pathways of SES, medication adherence, and clinical
outcomes(Chamberlain-Salaun et al., 2016; Ralph et al., 2016; Rémond et al., 2016a).
Summary and Conclusions
From this literature review, it can be seen that previous studies employed mainly
observational research designs such as cross-sectional and cohort studies to investigate
clinical outcomes in patients with RHD. In the same vein, this literature review also
shows that previous research to assess the relationship between SES, adherence, and
clinical outcomes in patients with RHD used both cross sectional and prospective cohort
designs. Several measures of SES were used in the literature, including family income,
geographic location of residence, and educational attainment. Measures of adherence to
BZP prophylaxis in previous studies include patient self-report and medical provider
assessments. Even though the BZP adherence rates seen in most of the studies reviewed
was sub-optimal, in some countries where RHD is endemic (India, Cuba and New
Zealand) the adherence rates were reported as good. However, there was varying
adherence rates reported for individual patients (0-100% of prescribed injections) with
some patients receiving inadequate BPG injections (adherence rates less than 80%) while
others received appropriate prophylaxis (Adherence rates greater than 80%). Due to the
observational nature of most of the studies reviewed, it was difficult to conclusively link
adherence to BPG with patient socioeconomic status.
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There are critical gaps in assessing patient self care with respect to chronic
disease management as seen from the literature reviewed. Socio-cultural factor was
identified as a key variable in predicting treatment adherence and health outcomes in
patients with chronic diseases.
In Chapter 3, I provided a description of the research design and justification for
the choice of the research design. In addition, I provided a description of the sample and
details of the selection criteria of study participants, description of the REMEDY study as
well as an overview of the variables in the study. The data collection process as well as
analysis was also discussed. The chapter concluded with a discussion of the ethical
considerations of this study.
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Chapter 3: Research Method
The aim of this study was to determine the relationship between SES and clinical
outcomes (incident heart failure and mortality rates) in patients with RHD. It also sought
to determine the role of adherence to BZP as a mediator between the relationship of SES
and clinical outcomes (Incident heart failure and mortality) in patients with RHD.
Research Design and Rationale
This research implemented a retrospective cohort design by using deidentified
secondary data from a previously collected data of RHD patients in Nigeria who
participated in a multicenter, multi-country prospective registry of patients with RHD,
called REMEDY to address the research questions. The REMEDY study prospectively
collected socio-demographic, clinical and echocardiographic data from 3343
symptomatic RHD patients presenting to the outpatient clinic, inpatient care facilities and
emergency room services of the 25 participating hospitals spread across 12 African
countries, India and Yemen between January 2010 and 2014. The Nigerian registry
contained 256 symptomatic RHD patients. Each patient was followed up over a 2-year
period (Karthikeyan et al., 2012; Zuhlke et al., 2014). Treatment adherence was
evaluated at each visit and clinical outcomes were recorded if it occurred during the study
follow-up period (Karthikeyan et al., 2012; Zuhlke et al., 2014). A cohort design was
appropriate for this secondary data analysis because of the need to compare two groups of
patients classified based on their SES (Gordis 2015). In addition, a cohort study design
helped to show the temporal sequence between the exposure (SES) and the outcome
(mortality, heart failure) since the subjects (RHD patients) are known to be free of the
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outcome of interest at the time of recruitment into the REMEDY study when their
exposure status was established (Gordis 2015). In a previous report of the clinical
outcomes in RHD patients prospectively studied, Zuhlke et al., (2015) had reported a
heart failure rate of about 7% and a mortality rate of 17% mostly in patients from low and
low middle income countries thereby underscoring the need for this retrospective cohort
study aimed at evaluating the relationship between individual level SES and clinical
outcomes in patients with RHD. (Zuhlke et al., 2015). I hypothesized that SES may affect
heart failure (HF) and mortality rates in patients with RHD. In addition, I also
hypothesized that the relationship between SES and clinical outcomes in these patients
will be influenced by their respective adherence to BZP prophylaxis (de Dassel et al.,
2018; Watkins et al., 2017). The availability of this secondary data already collected with
information on BZP adherence, HF rates and mortality rates provide an important
opportunity for testing these hypotheses (de Dassel et al., 2018; Gordis 2015). Secondly,
exploring how adherence mediates the association between SES and clinical outcomes is
needed to advance knowledge of mechanisms which may play a role in the SES-health
gradient even though the strength of the association between drug adherence and SES in
chronic diseases management is unclear (Choudhry et al., 2014;Dhar et al., 2017). RHD
being a chronic disease will thus benefit from an understanding of this mechanism on the
rates of adherence especially as it affects BZP adherence, an important but cost-effective
useful tool for management.
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Data Sources
Data for this secondary data analysis was obtained from the Nigerian site of the
global rheumatic heart disease registry (REMEDY) study. The REMEDY study enrolled
256 symptomatic RHD patients into the Nigerian registry at the point of contact with the
cardiologist in each participating hospital after obtaining written informed consent by a
trained research nurse. Socio-demographic data such as age, sex, educational attainment,
occupation, income and racial /ethnic affiliations were collected using a standardized
questionnaire after obtaining informed written consent (Karthikeyan et al., 2012; Zuhlke
et al., 2014). Clinical parameters were collected by the research clinician either from the
patient records or through oral interview as the case may be (Karthikeyan et al., 2012;
Zuhlke et al., 2014). Patient demographic data, clinical findings, and details of
electrocardiographic (ECG) and echocardiographic findings were recorded on structured
case record forms (Karthikeyan et al., 2012; Zuhlke et al., 2014). Details of medications
prescribed, with particular reference to penicillin prophylaxis, antithrombotic and
antiplatelet drugs, and antiarrhythmic medications, at study entry, 1-year follow-up, and
at the end of 2 years were also collected (Karthikeyan et al., 2012; Zuhlke et al., 2014).
Adherence to penicillin prophylaxis was assessed by obtaining injection records and/or
direct questioning (Karthikeyan et al., 2012; Zuhlke et al., 2014). Adherence to penicillin
prophylaxis was calculated based on percentage of prescriptions received over the 12
months preceding enrolment or follow up visits as the case may be (Karthikeyan et al.,
2012; Zuhlke et al., 2014). Echocardiography data was obtained in the echo laboratory or
if recently done, from the case records of the patient (Karthikeyan et al., 2012; Zuhlke et
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al., 2014). For improved diagnostic accuracy, standard operating procedures adapted
from the WHO guidelines for the diagnosis of RHD was used for uniformity in
classifying the patient as having RHD or not (Karthikeyan et al., 2012; Zuhlke et al.,
2014). Both the color and spectral Doppler signals must be holodiastolic for aortic
regurgitation or holosystolic for mitral regurgitation in order for a diagnosis of RHD to be
entertained (Karthikeyan et al., 2012; Zuhlke et al., 2014). The Doppler signal must be of
high velocity, either from a pulsed or continuous wave (Karthikeyan et al., 2012; Zuhlke
et al., 2014). These criteria can readily distinguish a small color jet of physiological
regurgitation in a normal person from pathological regurgitation in patients with RHD
(Karthikeyan et al., 2012; Zuhlke et al., 2014). Assessment of severity of valve lesions,
left ventricular (LV) systolic dysfunction (i.e. left ventricular ejection fraction, LVEF,
less than 54% or fractional shortening less than 28% in children and adults), and LV
dilatation (i.e. LV end diastolic dimension greater than 50 mm in children and 55 mm in
adults was done using the AHA guidelines). Patients in this study were identified through
registry data for inclusion (Karthikeyan et al., 2012; Zuhlke et al., 2014).
Follow-up—All patients recruited were made to undergo 2 follow-up visits, one at 12
months and one at 24 months (Karthikeyan et al., 2012; Zuhlke et al., 2014).
Echocardiogram was performed at both follow-up visits (Karthikeyan et al., 2012; Zuhlke
et al., 2014). In addition, assessment for outcomes (heart failure, ARF recurrence, death,
use of secondary benzathine penicillin prophylaxis, oral anticoagulation and surgical
intervention) was also done at each follow-up visit and at any other visits that the patient
makes to the hospital as part of usual care (Karthikeyan et al., 2012; Zuhlke et al., 2014).
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Outcomes were based on standard definitions (Karthikeyan et al., 2012; Zuhlke et al.,
2014). All deaths were recorded in a case record form and the cause ascertained by
review of the relevant source documents such as autopsy reports, physician records or in
the case of death at home an interview of a close relative or care giver who witnessed the
events preceding death by the managing physician (Karthikeyan et al., 2012; Zuhlke et
al., 2014). Morbidity such as new congestive cardiac failure was ascertained by review of
hospitalizations records of the patient as well as interview by the managing physician
(Karthikeyan et al., 2012; Zuhlke et al., 2014). Any additional information needed was
obtained by contacting one of the patient’s physicians or next of kin (Karthikeyan et al.,
2012; Zuhlke et al., 2014). For maintaining internal validity, an independent monitoring
board was constituted who at random select a sample of 10% of the locally adjudicated
events for audit in order to ascertain compliance with protocol and thus maintain
consistency with the study definitions (Karthikeyan et al., 2012; Zuhlke et al., 2014).
The data on these patients was coded so that no information can be linked to specific
individuals (Karthikeyan et al., 2012; Zuhlke et al., 2014). Patients were identified
throughout the study duration by the study number allotted to them at the time of
enrollment (Karthikeyan et al., 2012; Zuhlke et al., 2014). Confidentiality was maintained
by restricting access to de-identifiers to only the site PIs and in some cases by study
clinicians where there is need for medical intervention (Karthikeyan et al., 2012; Zuhlke
et al., 2014). The study data were archived by the principal investigator in the
department of Medicine, University of Cape Town. To access the data for this study, a
permission letter to access the data was submitted to the steering committee of the global
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rheumatic heart disease registry through the principal investigator. The steering
committee permitted my use of the data after reviewing my application and research
proposal.
Study Setting and Population
This study utilized a retrospective cohort design on data collected in Nigeria from
2010 to 2014 as part of the global rheumatic heart disease (REMEDY) study, a
multicenter, multi-country prospective study that collected data from symptomatic RHD
patients across 12 African countries, India and Yemen (Karthikeyan et al., 2012; Zuhlke
et al., 2014). The Nigerian site consisted of 5 participating centers spread across the north
(Aminu Kano Teaching Hospital, Kano), central (Jos University teaching Hospital, Jos
and University of Abuja Teaching Hospital, Gwagwalada) and southern parts of the
country (University College Hospital, Ibadan and Federal Medical Center, Abeokuta).
Symptomatic RHD patients were recruited from outpatient clinics, emergency rooms and
inpatient care wards at baseline and subsequently followed up over two years at the
participating sites (Karthikeyan et al., 2012; Zuhlke et al., 2014). This study formed two
cohorts based on the socioeconomic groupings as classified using Oyedeji socioeconomic
classification system (Oyedeji 1985). The socioeconomic variables used were those
variables collected on the patients at the time they were recruited into the REMEDY
study (Zuhlke et al., 2014). One cohort (Cohort 1) contained patients with low SES while
the second (Cohort 2) contained patients with middle to higher SES. SES classification
was done based on the educational attainment and occupation of the patients themselves
or their caregivers in case of children as proposed by Oyedeji (Oyedeji 1985).
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The baseline characteristics included age at entry, sex, educational attainment for
adults or parental educational attainment for children, weight, height, disease severity at
enrolment, heart failure status, New York Heart Association (NYHA) class and
benzathine penicillin prophylaxis status at enrolment. The outcome for heart failure was
identified based on the report of events such as hospitalization or treatment for heart
failure as reported by the managing physician and documented in the case record form
(CRF) (Karthikeyan et al., 2012; Zuhlke et al., 2014). The mortality was based on
physician CRF report, autopsy report or family report as detailed in the study events
forms (Karthikeyan et al., 2012; Zuhlke et al., 2014). The follow-up time for each patient
was counted from day of entering the study to onset of the study outcome or end of the
study (Karthikeyan et al., 2012; Zuhlke et al., 2014).
Power Calculations
Power analysis was conducted using G*Power (version 3.0.10) based on a
Poisson regression model in order to determine the needed sample size (Cumming 2012;
Kline 2013). In this calculation, using a significance level of 0.05, effect size of 0.3
(Kline 2013), z statistics of 1.959964 and a power of 0.80, the total minimum study
population needed to answer research question 1 is 130 (65 in each cohort). However, all
patients contained within the Nigerian database of the REMEDY study were recruited
into the study (Kline 2013). The calculation output is depicted in figure below.
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Figure 1. Showing cases needed for research questions α is the rejection zone while β is
the type 2 error rate.
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Data Collection Procedure
This study utilized the data collected from the REMEDY study (Karthikeyan et
al., 2012; Zuhlke et al., 2014). The REMEDY study had collected clinical, sociodemographic, and echocardiographic data from all the patients enrolled into the registry
using an eleven-page questionnaire that is divided into sections for ease of administration
at baseline, 12 months and 24 months (Karthikeyan et al., 2012; Zuhlke et al., 2014).
Each section began with standard operating procedures, codes and definition of variables
to be collected in that section (Karthikeyan et al., 2012; Zuhlke et al., 2014). The first
page contained questions on sociodemographic variables such as age, gender, education,
ethnicity, income and occupation (Karthikeyan et al., 2012; Zuhlke et al., 2014). The next
eight pages contain questions about the clinical history of the patient including
echocardiography information as well as other investigations done (Karthikeyan et al.,
2012; Zuhlke et al., 2014). The last 2 pages contain drug history of the patient and
information on number and adherence to BZP injection (Karthikeyan et al., 2012; Zuhlke
et al., 2014). A sample of the questionnaire is attached as Appendix A. Each patient was
recruited at baseline by a research nurse after obtaining written informed consent
(Appendix B). These patients were subsequently followed up annually for 2 years
(Karthikeyan et al., 2012; Zuhlke et al., 2014). At each visit, the patients were assessed
for the occurrence of adverse outcomes (such as death, congestive heart failure (CHF),
stroke or transient ischemic attack (TIA), recurrence of acute rheumatic fever (ARF), and
infective endocarditis (IE)), use of secondary antibiotic prophylaxis and oral
anticoagulation medication, and need for valve intervention or surgery (Karthikeyan et
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al., 2012; Zuhlke et al., 2014). The study had a standard protocol for the diagnosis of all
outcomes including congestive cardiac failure and death (Karthikeyan et al., 2012;
Zuhlke et al., 2014).
Definition of Variables
Independent Variable
Socioeconomic status (SES). In epidemiological research, various indicators of
SES have been used. Depending on the context, the population studied and the outcome
measured, any of income, wealth, education and occupation may be used in isolation or
in any combination in assessing SES (Oakes & Rossi, 2003). Socioeconomic status
(SES), a fundamental construct in the social and health sciences, is a measure of access to
resources, such as financial resources and material goods, power, social networks, health
care, and educational opportunities (Oakes & Rossi, 2003). SES indicates one’s position
in the social hierarchy, and often determines one’s life chances. It is thus a summary of
one’s access to wealth and opportunities and hence defines one’s social hierarchy (Oakes
& Rossi 2003). In the current study, SES was used as a measure of social class position
(Galobardes et al. 2006; Oakes & Rossi 2003). Using the Oyedeji SES classification, SES
was derived from a combination of educational attainment and occupation class (Oyedeji
1985). In case of a child, the mean of four scores (two for the father and two for the
mother) to the nearest whole number is the social class assigned to the child. I-II: UPPER
CLASS, III-V: LOWER CLASS
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Table 1
Showing Oyedeji social classification scheme
Social class

Profession

I

Professional, Senior public servants, owners of
large business concerns, Senior military
officers, large scale contractors.

II

Non-academic professionals e.g. Nurses,
Secondary school teachers, secretaries, Owners
of medium sized business. Intermediate grade
public servants.

Educational
attainment
University graduates
or equivalents.
School certificate
holders and
equivalents

III

IV

Non manual skilled works including clerks,
typists, telephone operators, Junior school
teachers, Drivers

Grade II teachers or

Petty traders, Laborers, Messengers

Primary School

equivalent

certificate
V

Unemployed, Full time housewives, students,
subsistence farmers

No formal education
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Dependent Variables
The dependent variables were clinical outcomes defined as the presence of any
death (mortality) or Heart failure events.
Mortality refers to deaths in the study population. The REMEDY study had used events
forms to encode deaths either in the hospital or at home (Karthikeyan et al., 2012; Zuhlke
et al., 2014). In case of any death during the study period, the physician fills a death
report form using autopsy report for those patients who consented to autopsy, death
certificate reports or verbal communication of events from the family in the case of
patients who died at home (Karthikeyan et al., 2012; Zuhlke et al., 2014). The study
counted all-cause mortality and specific type of mortality e.g. deaths from heart failure,
rheumatic fever, infective endocarditis etc. This variable was adopted and used in the
secondary data analysis.
Heart failure events. All patients recruited into the REMEDY study had a heart failure
events form filled by each study clinician (Karthikeyan et al., 2012; Zuhlke et al., 2014).
New onset or repeat heart failure occurring in each patient during the 2 year follow up
period was reported and encoded into the heart failure events form (Karthikeyan et al.,
2012; Zuhlke et al., 2014). Heart failure was diagnosed if any 2 of the following 3 criteria
were present: (1) symptoms (dyspnea on exertion or at rest, orthopnea, nocturnal
paroxysmal dyspnea, or ankle edema) or signs (rales, increased jugular venous pressure,
or ankle edema) of CHF; (2) radiological signs of pulmonary congestion; and (3)
treatment with diuretics (Karthikeyan et al., 2012; Zuhlke et al., 2014). This variable was
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adopted and used in the secondary data analysis (Karthikeyan et al., 2012; Zuhlke et al.,
2014).
Adherence has been consistently defined as “the extent to which a person’s behavior (in
terms of taking medications, following diets, or executing lifestyle changes) coincides
with medical or health advice” (Haynes, Taylor & Sackett 1979, p.1-2). It is thus seen as
the behavior of the patients or care givers who bear responsibility for ensuring the
patients visit the nurse for the 4 weekly BZP injection. This is supported by previous
study done on adherence rates to therapy in chronic disease management (Orrell-Valente
& Cabana 2008). In the REMEDY study, adherence rate was conceptualized as the
number of times an individual with RHD received prescribed 4 weekly benzathine
penicillin (BZP) in the one-year period of study (Karthikeyan et al., 2012; Zuhlke et al.,
2014). It was represented as a ratio (%) between the actual monthly injections and
expected number of monthly injections in a year (Karthikeyan et al., 2012; Zuhlke et al.,
2014). For the purpose of this study, the same adherence rate was adopted (Zuhlke et al.,
2015). Thus, the patient actual number of BZP received during the period of observation
was divided by the total expected number of BZP injections and expressed as a
percentage ratio (Zuhlke et al., 2015).
Adherence rate (%) = Number of actual BZP injections received in a year
Number of expected BZP injections in a year
The adherence rate was then coded into one of the following clinically significant ordinal
categories: low (<35%), medium (36-79%), and high (≥80%) (Karthikeyan et al., 2012;
Zuhlke et al., 2015). A patient with rheumatic heart disease is expected to receive at least
80% of the annual prescribed injections (Cannon et al., 2017; Carapetis et al., 2012).
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When an individual patient receives less than 80% of the injections, they are at a higher
risk of recurrent ARF and its complications (Cannon et al., 2017; Carapetis et al., 2012).
For the purpose of this study, benzathine penicillin prophylaxis adherence was classified
as good (≥80%) and poor (< 80%) adherence rate.
Covariates. Control variables (covariates) for this study included age, sex, disease
severity at enrolment, heart failure status at enrolment, NYHA class at enrolment and
number of months since diagnosis with RHD (Karthikeyan et al., 2012; Zuhlke et al.,
2014). According to Creswell (2009), control variables are a “special type of independent
variable…because they potentially influence the dependent variable” (p. 51). Age at last
birthday will be used during data preparation for analysis. Gender and socioeconomic
status will be measured as categorical variables on a nominal scale.
Analyses
The IBM Statistical Package for the Social Sciences (SPSS) Statistics 23 (SPSS
23) was used in the analysis of the data. The IBM SPSS 23 is a systematic tool that helps
with data evaluation with precise results that allows one to assess all outcomes of interest
(IBM, 2015). This statistical software is a suitable choice for my data analysis because of
the availability of descriptive and inferential analysis features suitable for the dataset that
I used in this study.
Handling Missing Data
Being a secondary data analysis, missing data can be a challenging problem
resulting from incomplete data entry giving rise to some data fields having missing
values (CDC 2010). The dataset was thus evaluated for missing values. Less than 10% of
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the variables had missing data; thereby providing no need for further adjustments or
modifications (CDC, 2010).
Descriptive Statistics
Socio-demographic characteristics (age, sex, weight, height, educational
attainment, occupation, and income, clinical characteristics (RHD severity, HF etc) and
echocardiographic parameters (EF, LVEDD) comparisons between the two cohorts were
done using descriptive statistics. The difference between the two cohorts was described
using Student t test for continuous variables such as age, EF and LEVDD and chi square
for categorical variables such as sex, educational attainment and occupation.
Analyses method to address each question
Research question (RQ)1:
Does the number of heart failure events differ between RHD patients of low SES
and RHD patients of higher SES?
Null hypothesis (H01): There is no difference in number of heart failure events
between RHD patients of low SES and RHD patients of higher SES.
Alternate hypothesis (Ha1): There is a difference in number of heart failure events
between RHD patients of low SES and RHD patients of higher SES.
For this study, HF was measured as the number of heart failure events occurring
among patients with RHD over the two year follow up period (Gordis 2015; Hagenaars
2018). This is a continuous variable measured as a count or frequency of occurrence of
repeat HF events in each patient (Gordis 2015; Hagenaars 2018). Poisson regression
analysis was used to compare the differences between the two cohorts. Poisson regression
methods was used in assessing the difference in HF events between the two SES
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groupings. Poison regression analysis was chosen because it is a generalized linear model
that models count data. The Poisson regression is chosen because of the assumption that
HF events changes linearly with equal increment, the changes in the, HF events from
combined effects of different confounders (such as age, gender etc) are multiplicative,
that at the each level of the covariates the number of cases has variance equal to the mean
and that the observations are independent. The plots of residuals versus the mean at
different levels of the predictor variable was used to determine violations of assumption
or to ascertain whether variances are too large or too small. It is the appropriate statistics
here because the dependent variable (heart failure) is a count of events occurring over a
time period.
Research question (RQ)2:
Does the mortality rate differ between RHD patients of low SES and RHD
patients of higher SES?
Null hypothesis (H02): There is no difference in mortality rates between RHD
patients of low SES and RHD patients of higher SES.
Alternate hypothesis (Ha2): There is a difference in mortality rates between RHD
patients of low SES and RHD patients of higher SES.
Mortality refers to the occurrence of death in a defined population during a specified time
period (Gordis 2015; Hagenaars 2018). For this study, mortality was measured as the
number of deaths occurring among patients with RHD over the two year follows up
period (Gordis 2015; Hagenaars 2018). This is a categorical variable measured on the
nominal scale (Gordis 2015; Hagenaars 2018). Mortality was measured as present (death)
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or absent (alive) in the patients with RHD over the two year follows up period. Logistic
regression analysis was used to compare the mortality rate between the two cohorts.
Research Question (RQ) 3:
Is there a significant difference in the number of heart failure events between
RHD patients of low SES and RHD patients of Higher SES when adjusting for the effect
of benzathine penicillin prophylaxis adherence?
Null hypothesis (H03): There is no significant difference in the number of heart
failure events between RHD patients of low SES and RHD patients of Higher SES after
adjusting for the effect of benzathine penicillin prophylaxis adherence rates.
Alternate (HA3): There is a significant difference in the number of heart failure
events between RHD patients of low SES and RHD patients of Higher SES when
adjusting for the effect of benzathine penicillin prophylaxis adherence rates.
In answering Research Question 3, Poisson regression model with mediation
analysis was used by considering three variables, SES (independent), BZP adherence
(independent), and heart failure (dependent). I analyzed whether adding BZP adherence
to the Poisson regression model mediates the relationship between SES and heart failure.
Poison regression analysis was chosen because it is a generalized linear model that
models count data like rates. In addition, it was chosen because of the assumption that
heart failure changes linearly with equal increment, the changes in the number of heart
failure events from combined effects of different confounders (such as age, gender etc)
are multiplicative, that at the each level of the covariates the number of cases has
variance equal to the mean and that the observations are independent. The plots of
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residuals versus the mean at different levels of the predictor variable was used to
determine violations of assumption or to ascertain whether variances are too large or too
small. Using Poisson regression gave me the opportunity to analyze interrelationships
among multiple risk factors or exposure variables and a single outcome (Sullivan, 2012).
It is the appropriate statistics here because the dependent variable (heart failure) is a
count of events occurring over a time period.
Research question (RQ) 4:
Is there a significant difference in the risk of dying (mortality) between RHD
patients of low SES and RHD patients of Higher SES when adjusting for the effect of
benzathine penicillin prophylaxis adherence?
Null (H03): There is no significant difference in risk of mortality between RHD
patients of low SES and RHD patients of Higher SES after adjusting for the effect of
benzathine penicillin prophylaxis adherence rates.
Alternate (HA3): There is a significant difference in risk of mortality between
RHD patients of low SES and RHD patients of Higher SES after adjusting for the effect
of benzathine penicillin prophylaxis adherence rates.
In answering research question 4, multivariable logistic regression with mediation
analysis was used by considering three variables, SES (independent), BZP adherence
(independent), and mortality (dependent). I analyzed whether adding BZP adherence to
the multivariable logistic regression model mediate the relationship between SES and
mortality. Stepwise (forward regression) method was used in conducting the regression
analysis. In addition, statistical significance of the indirect effects of mediation was tested

61
using bootstrapping method (Preacher, & Hayes, 2008). Using Multivariable statistics
gives me the opportunity to analyze interrelationships among multiple risk factors or
exposure variables and a single outcome as stated in the analysis for RQ2 (Sullivan,
2012).
Threats to Validity
The data collected from the REMEDY study on patient drug treatment adherence
is based on the patient’s self-report. Self-reported measures of adherence are a potential
threat to internal validity because of the tendency to overestimate adherence rates
(Dunbar-Jacob, Schlenk, & McCall, 2012). Patients (and their care givers in the case of
minors) in a bid to recall past events may inaccurately recall information about missed
medication doses (Gordis 2015; Dunbar-Jacob et al., 2012) Socially desirable response
when questioned by their primary care provider especially that which helps to cast them
in a good light before their primary care provider is also likely to occur (Gordis 2015;
Dunbar-Jacob et al., 2012) Recall bias, social desirability bias, and errors in selfobservation may contribute to an overestimation of adherence (Gordis 2015; DunbarJacob et al., 2012). In addressing these biases, the REMEDY study protocol used
standard operating procedures with uniform definitions for terms and variables used. In
addition, patient records and in some cases phone conversation with managing primary
care physician were used in order to improve the quality of information.
The REMDY study used symptomatic RHD patients who presented in the
hospital for treatment. The exclusion of asymptomatic patients might have introduced
some form of self selection. These patients may thus not be representative of the target
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population of all patients with RHD considering the fact that access to care and disease
severity might have played a role in their presentation. However, by ensuring that patient
recruitment follows the approve research protocol at each site through the use of standard
operating procedures and definition of terms for all variables and outcomes variables, the
usability of the findings in the target population of patients with RHD globally was
enhanced and thus the external validity
The REMEDY study collected data from patients after obtaining IRB approval
and protects all information as required in accordance with the HIPPA act. In addition,
written informed consent was obtained from all participants before and during the entire
period of study. No patient was denied care nor was care linked to participation in the
study. Walden University IRB was however sought and obtained for the current study.
There is no need for a fresh written informed consent from the patients as REMEDY had
originally informed the patients about the possibility of using their data for future
publications. The data was anonymized, password protected and electronically
transmitted from the REMEDY data manger after due permission was obtained from the
principal investigator. Access to all data was restricted. After the successful defense of
this dissertation study, the data will be stored in this manner for 5 years and then
destroyed subsequently.
Ethical Considerations
Deidentified data contained within the Nigerian register of the REMEDY study
registry for RHD was used. Patient data and information was protected as required by
federal law section 308 (d) of the Public Health Service Act and the Privacy act of 1974.
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Walden Institutional Review Board approval (IRB approval number 12-04-19-0550282)
was obtained before embarking on this study.
Summary
In summary, this was a secondary data analysis of a prospectively collected data
utilizing data from the REMEDY study, a multicenter, international registry of patients
with RHD seen in 25 facilities spread across 12 African countries, India and Yemen. The
study was a retrospective cohort study utilizing secondary data analysis of datasets of
patients with RHD collected in a longitudinal, prospective study in Nigeria. The study
examined the association between SES and clinical outcomes in patients with RHD seen
in inpatient, emergency room and outpatient departments of these developing countries.
In addition, the effect of adherence to benzathine penicillin, a treatment option shown to
impact outcome in RHD management on the relationship between SES and clinical
outcomes was assessed.
The IBM SPSS version 23 was used for all analysis. Student t test and chi square
was used in comparing the baseline characteristics of the cohort being evaluated. Poisson
regression analysis was used to examine the relationship between SES and heart failure
(RQ1) and also the mediator role of adherence to BZP prophylaxis in the relationship
between SES and heart failure (RQ3). Multivariable regression was used to assess the
relationship between SES and mortality rates (RQ2)., and the mediator role of adherence
to BZP prophylaxis in the relationship between SES and mortality (RQ4).
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Chapter 4: Results
Introduction
The purpose of this secondary data analysis was to assess the relationship between
individual level SES and clinical outcomes (heart failure events and mortality) in patients
with RHD as well as examine how adherence to benzathine penicillin prophylaxis
mediates the effect of socioeconomic status on clinical outcomes (heart failure events and
mortality rate) for these patients with RHD. Data from 198 symptomatic RHD patients in
Nigeria were used to address the following research questions and hypotheses:
RQ1. Does the number of heart failure events differ between RHD patients of low
SES and RHD patients of higher SES?
H01: There is no difference in number of heart failure events between RHD
patients of low SES and RHD patients of higher SES
HA1: There is a difference in number of heart failure events between RHD
patients of low SES and RHD patients of higher SES
RQ2: Does the risk of mortality differ between RHD patients of low SES and
RHD patients of higher SES?
H02: There is no difference in risk of mortality between RHD patients of low SES
and RHD patients of higher SES
HA2: There is a difference in risk of mortality between RHD patients of low SES
and RHD patients of higher SES
RQ3: Is there a significant difference in number of heart failure events between
RHD patients of low SES and RHD patients of Higher SES when adjusting for the effect
of benzathine penicillin prophylaxis adherence?
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H03: There is no significant difference in number of heart failure events between
RHD patients of low SES and RHD patients of Higher SES after adjusting for the effect
of benzathine penicillin prophylaxis adherence rates.
HA3: There is a significant difference in number of heart failure events between
RHD patients of low SES and RHD patients of Higher SES after adjusting for the effect
of benzathine penicillin prophylaxis adherence rates.
RQ4: Is there a significant difference in risk of mortality between RHD patients
of low SES and RHD patients of Higher SES when adjusting for the effect of benzathine
penicillin prophylaxis adherence?
H04: There is no significant difference in risk of mortality between RHD patients
of low SES and RHD patients of Higher SES after adjusting for the effect of benzathine
penicillin prophylaxis adherence rates.
HA4: There is a significant difference in risk of mortality between RHD patients
of low SES and RHD patients of Higher SES after adjusting for the effect of benzathine
penicillin prophylaxis adherence rates.
In this chapter, I discuss the results of this study in relation to the research
questions, hypothesis, sample characteristics, and descriptive analysis used in this study.
Data Collection
Secondary data analysis was conducted using de-identified data from the Nigerian
site of the REMEDY study; a registry based longitudinal study of symptomatic RHD
patients that collected clinical, sociodemographic, and echocardiographic data from all
the patients enrolled into the registry using an eleven page questionnaire that is divided
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into sections for ease of administration at baseline, 12 months and 24 months. These
patients were categorized into two cohorts based on their SES classification for Nigerian
and developing settings as proposed by Oyedeji. The study received IRB approval from
Walden University.
Descriptive statistics
Demographic characteristics
There were 198 RHD patients in the Nigerian register of the REMEDY study. A
total of 15 (7.6%) of the participants were missing key variables for analysis and so were
excluded.
The mean age of the participants was 24.2 years with a standard deviation of 13.9
years. The median age was 21.1 years; 95% confidence interval (CI) = 8.9 – 53.0 years.
A total of 110 (60.1%) of the participants were from the low SES group while 73 (39.9%)
were from the higher SES group (χ2 =3.95, p=0.08). participants
Table 2 presents data on the demographic and clinical characteristics of the 183
subjects with RHD that were studied. The two SES groups were similar in sex
composition (χ2 =1.50, p = 0.62), and age group distribution (χ2 =2.55, p = 0.13). The
clinical parameters were also similar for the two groups at baseline. The groups were
similar in past history of heart failure (χ2 =3.65, p = 0.06), disease severity at baseline (χ2
=0.07, p=0.86) and BZP prophylaxis adherence at baseline (χ2 =0.98, p = 0.36).
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Table 2
Demographic and Clinical Characteristics of 183 Subjects with RHD by SES grouping
Variable

Low SES

Higher SES

Total

N=110

N=73

N=183

n (%)

n (%)

n (%)

p

Female

85(76.6)

46(61.2)

131(71.6)

0.08

Male

25(23.4)

27(28.8)

52(28.4)

Adult

77(66.4)

40(59.7)

117(63.9)

Child

39(33.6)

27(40.3)

66(36.1)

Yes

75(67.0)

38(53.5)

113(61.7)

No

37(23.0)

33(46.5)

70(38.3)

Mild

85(75.9)

56(78.9)

141(77.0)

Severe

27(24.1)

15(21.1)

42(23.0)

Yes

40(36.4)

33(45.2)

73(39.9)

No

70(63.6)

40(54.8)

110(60.1)

Socio-demographic
Sex

Age category
0.62

Clinical Parameters
Past History of Heart
failure
0.06

Disease Severity
0.72

BZP Prophylaxis

Note. SES= Socioeconomic status

0.36
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Table 3 presents data on the anthropometric and echocardiography parameters of
the 183 subjects with RHD that were studied. The two groups were similar in mean
weight, height and BMI distribution (p=0.72, 0.71 and 0.94 respectively).
Echocardiography parameters were also comparable between the two groups. Left
ventricular end diastolic dimensions (LVEDD) was similar (t=0.95, p=0.35), ejection
fraction (EF) was similar for both groups (t=0.63, p=0.53), fractional shortening (FS) was
similar as well (t=0.25, p=0.84).
Table 3
Comparison of Anthropometric and Echocardiographic Parameters at Baseline by SES
grouping
Low SES
Higher SES
Anthropometric
Mean
SD
Mean
SD
Parameters

P value

Weight (Kg)

48.3

17.3

49.3

16.6

0.72

Height (m)

1.52

0.16

1.55

0.16

0.71

BMI(Kg/m2)

20.0

4.49

20.0

4.71

0.94

Person years

1.83

0.76

2.01

0.71

0.11

LVEDD

55.7

11.5

53.8

13.2

0.35

EF (%)

55.5

15.5

57.0

15.4

0.53

FS (%)

30.4

9.8

30.8

8.9

0.84

Echocardiography
Parameters

Note. EF= Ejection fraction, FS= fractional shortening, LVEDD= left ventricular end
diastolic dimensions
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Table 4.
Comparison of Number of Persons Ever Had Heart Failure by SES grouping
Variable
N
Mean SD t
p value
Lower SES 110 10.O 3.1 2.20 0.03
Higher SES 73 3.0
3.0

Table 4 presents data on number of patients with heart failure in the study. Ten RHD
patients from lower SES group ever had heart failure compared with 3 from higher SES
group (Mean=3.1, p=0.03).
Table 5
Comparison of Mean Heart Failure Events by SES grouping
Variable
N
Mean Min Max p value
Lower SES 110 26
18
44
0.05
Higher SES 73 14
6
22

Table 5 presents data on number of heart failure events in the study. There were 26 heart
failure events recorded in patients from lower SES group compared with 14 events
recorded from patients from higher SES group (Mean=3.1, p=0.03).
Research Question 1: The Relationship between SES and heart failure events
What is the relationship between socioeconomic status and heart failure events in
patients with rheumatic heart disease? The null hypothesis was that there is no difference
in number of heart failure events between RHD patients of low SES and RHD patients of
higher SES. The alternate hypothesis is there is a difference in number of heart failure
events between RHD patients of low SES and RHD patients of higher SES. Heart failure
events refers to the number of times each patient developed heart failure in the course of
the 2 years follow up. Based on descriptive statistics on Research Question 1 variables,
potential confounders assessed by bivariate statistics are age, person year of follow up

70
and disease severity at baseline. Poisson regression to compare heart failure events
before and after adjusting for these potential confounders was conducted.
Poisson regression. The crude heart failure events (HF) were first calculated for
the groups before conducting the Poisson regression. Lower SES group RHD patients had
cumulatively 26 (23.6%) heart failure events compared with their higher SES
counterparts who had 14 (19.2%) heart failure events (p-0.04, ℵ2 =4.972). Poisson
regression analysis of heart failure events (dependent variable) on SES groupings
(independent variable) was performed to compare the difference in heart failure events
between RHD patients in the lower SES group and RHD patients in the higher SES
group. I used the grouped data analysis approach and also log-transformed the personyear variable where it is used as an off-set variable in fitting the Poisson regression
model. The Poisson regression model is defined in terms of log of expected counts HF as:
Loge (Y)= β0 + β1X1, where the X represents the explanatory variable (SES). The
distribution of the count variable (heart failure events) was checked to see if it followed
Poisson distribution using one sample KS statistics (p=1.00) and descriptive statistics
(mean count=0.07 variance=0.066). From this, I assumed that heart failure event was
approximately Poisson distributed since the model had a very strong assumption; that is,
the mean of the research data was approximately equal to the variance of the data.
The Poisson model, used in this analysis, fit reasonably well the research data
because the goodness-of-fit chi-square test was not statistically significant, p = 1.0 (Table
6). If the test had been statistically significant, it would have indicated that the data did
not fit the model well.
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Table 6
Model Goodness of Fit
Value
92.980
828.259

Likelihood ratio
Pearson Chi-Square

df
166
166

Sig.
1.000
1.000

Model parameter estimates include the regression coefficients for each of the
predictor variables along with p-values and 95% confidence intervals for the coefficients.
The number of heart failure events among RHD patients was then predicted by the
exponentiated coefficient, exp (B), or the regression incidence rate ratio. The exp (B) for
RHD patients in the low SES group was 4.379 while that of the comparison group (higher
SES) was 1.00. Based on these results, the RHD patients from low SES group would be
4.8 times more likely to experience heart failure events compared with their counterparts
from a higher SES group (Table 7). This was significant (p=0.04).

Table 7
Poisson Regression Analysis of Heart Failure Events on SES Group
Hypothesis Test
SE

Wald

p

95% CI for OR

Parameter

B

OR

(Intercept)

-5.769

.7071

66.560

0.00

.003

Lower SES

1.563

.7638

4.186

0.04

4.771

Lower
.001

Upper
.012

1.068 21.318

Dependent Variable: Heart failure rate, Model: (Intercept), SES, offset = person year
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Considering the above findings, I will thus reject the Null Hypothesis 1 since
heart failure was found to be significantly associated with lower SES compared with
higher SES grouping.
Research Question 2: The Relationship Between SES and Mortality Rate
Bivariate Analyses
Before constructing the model for multivariable logistic analyses, I conducted
bivariate statistics (chi square) using cross tabulations to examine the potential
confounders across the independent variable and dependent variables. Disease severity at
baseline and BZP adherence rates were significantly associated with mortality.
Logistic Regression Analyses
I used binomial logistic regression to analyze the relationship between SES
grouping and mortality. All the variables included in the model are categorical. Mortality
was coded as 0 if it did not occur and 1 if it occurred. For this logistic regression, death
(mortality occurring) was the dependent variable. SES was grouped to low SES group
and higher SES group. For this logistic regression, lower SES was the reference group.
Eight participants were dropped from the initial analysis due to missing data resulting in a
sample of 190 participants. From my initial analysis, of all the potential confounders,
only diseases severity and BZP adherence were significantly associated with the
dependent and independent variables. In the final model, only 15 participants were
dropped because of missing variables leaving 183 participants in the analyses. The
parameter estimates from the logistic regression model showed that the odds of dying
(mortality) is approximately 42% lower for RHD patients in the lower SES group
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compared to RHD patients in the higher SES group (OR=0.58; 95% CI 0.26- 1.29). The
result is not statistically significant because the 95% confidence interval does include 1
and p = 0.18. I will thus not reject the Null hypothesis. Therefore, there is no statistically
significant association between SES and mortality in RHD patients aged 5 to 60 years
seen in Nigeria (Table 8).
Table 8
Logistic Regression Model Coefficients of SES with Mortality

Variable
Intercept
Lower SES

OR
0.48
0.58

95% CI

P

LL

UL

0.26

1.29

0.19
0.18

Research Question 3: The Relationship Between SES and Number of Heart Failure
Events When Considering the Possible Effect of Adherence to Benzathine Penicillin
(BZP) Prophylaxis
In mediation analysis, the three main effects of interest are the (a) total effect, (b)
direct effect, and (c) indirect or mediation effect of exposure on outcome (Mascha,
Dalton, Kurz, & Saager, 2013). SES grouping is the exposure, and number of heart
failure event is the outcome. I examined adherence to BZP prophylaxis as a mediator of
SES and number of heart failure events. The total effect of SES on heart failure events
does not adjust for adherence to BZP prophylaxis. According to Mascha,Dalton, Kurz,
and Saager (2013), the total effect of an exposure on an outcome includes adjustment for
confounding variables but ignores the specified mediator. Using Poisson regression as in
RQ1, the total effect of SES on heart failure events after adjusting for age and disease
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severity as confounders was first calculated. SES group 1(low SES group) was found to
be 4.8 times more likely to develop heart failure events compared with SES group 2
(higher SES group) with person years of follow up as the offset variable (OR = 4.77, 95%
CI [1.07, 21.32]). Next, the effect of BZP adherence on heart failure events was
calculated. Poor BZP adherence was 58% more likely to develop a heart failure event
compared with those with good BZP adherence (OR = 0.42, 95% CI [0.12, 1.45]).
Subsequently, the effect of SES on heart failure events with BZP adherence in the model
with age and disease severity as confounders (covariates) and person years of follow up
as offset variable was calculated. Table 9 displays the final model coefficients after
including the mediator variable (adherence to BZP prophylaxis). Lower SES was
associated with a 4.6 times likelihood of developing heart failure event compared with
those in higher SES (OR = 4.57, 95% CI [1.02, 20.43]. The effect of the mediator
variable, BZP prophylaxis is also shown. Patients with good BZP adherence were 55%
less likely to develop heart failure event compared with those with poor BZP adherence
(OR=0.45, 95% CI [0.12, 1.58, p=0.21).
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Table 9
Poisson Regression Model Coefficients of SES on Heart Failure with Adherence as a
Mediator

Parameter
(Intercept)

B
-5.495

SE
.7261

Lower SES

1.519

.6598

Hypothesis Test
Wald
p
57.278
0.00
3.949

0.04

OR
0.004
4.567

95% CI for OR
Lower Upper
.001
.017
1.021

20.43

Good
-.809
.6518
1.540
0.22 0.445
0.12 1.598
Adherence
Dependent Variable: Heart failure events, Model: (Intercept), SES, offset = person year
SE=Standard error, CI=confidence interval, OR=Odds ratio, LL=lower limit, UL=upper
limit
In order to prove mediation, the mediator variable must affect the outcome
variable independent of the exposure variable (Mascha et al., 2013). Adherence to BZP
prophylaxis was not significantly associated with heart failure events independent of SES
as the p-value is 0.22. However, the relationship between SES and heart failure remains
significant even though the effect size (OR) is slightly less than that without the mediator
variable (4.77 vs 4.56). This shows partial mediation and so the null hypothesis is thus
rejected. Adherence partially mediate the relationship between SES and heart failure
events. Therefore, adherence to BZP partially mediates the effect of SES on the odds of
developing heart failure events in patients with RHD contained within the Nigerian
registry of REMEDY.
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Research Question 4: The Relationship Between SES and Mortality Rate When
Considering the Possible Effect of Adherence to Benzathine Penicillin (BZP)
Prophylaxis
As seen in research question 3, for mediation analysis, the three main effects of
interest are the (a) total effect, (b) direct effect, and (c) indirect or mediation effect of
exposure on outcome (Mascha, Dalton, Kurz, & Saager, 2013). SES grouping is the
exposure, mortality rate is the outcome. I examined adherence to BZP prophylaxis as a
mediator of SES and mortality.
The total effect of SES on mortality does not adjust for adherence to BZP prophylaxis.
According to Mascha,Dalton, Kurz, and Saager (2013), the total effect of an exposure on
an outcome includes adjustment for confounding variables but ignores the specified
mediator. The total effect of SES on mortality after adjusting for confounders was first
calculated. Here, SES group 1(low SES group) was found to be 62 % less likely to
develop mortality compared with SES group 2 (higher SES group) when the potential
confounders (age category, sex, person years of follow up, disease severity at baseline)
were adjusted for in the logistic regression model (OR = 0.38, 95% CI [0.04,4.09].
The direct effect of SES on incident heart failure rate which is the effect that is
independent of adherence to BZP prophylaxis was then calculated next. Table 10 displays
the final model coefficients after including the mediator variable (adherence to BZP
prophylaxis). Here, SES group 1(low SES group) is now about 48.8% likely to die when
mediator is added to the binomial logistic regression model (OR=0.51, 95% CI =0.04 7.03). The effect of the mediator variable, BZP prophylaxis is also shown. Poor
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adherence is 3.28 times more likely to be associated with mortality compared with good
adherence (OR=3.28. 95% CI=0.42. 25.78. p=0.26)
Table 10
Logistic Regression Model Coefficients of SES with Mortality and Adherence as a
Mediator
Variable

B

OR

95% CI
LL
UL

P
value
0.001

Intercept

-13.599

Poor adherence

1.19

3.28

0.42

25.78

0.26

Severe RHD

1.47

4.35

0.32

59.17

0.27

Lower SES

-.67

0.51

0.04

7.03

0.62

Age ≥18 years

2.06

7.83

0.47

130.72

0.15

Female

1.86

6.42

0.37

112.84

0.20

Person year

6.54

694.24

26.38

18270.36

SE=Standard error, CI=confidence interval, OR=Odds ratio, LL= lower limits, UL=
upper limits SES= Socioeconomic class, RHD=rheumatic heart disease
In order to prove mediation, the mediator variable must affect the outcome
variable independent of the exposure variable (Mascha et al., 2013). Adherence to BZP
prophylaxis was not significantly associated with mortality independent of SES as the pvalue is 0.073. However, the person year of follow up was significantly associated with
mortality as the p value is <0.001. (Table 10). The null hypothesis is thus not rejected.
Adherence does not mediate the relationship between SES and mortality.

<0.001
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Summary
This chapter presented the results of regression analyses to examine the
relationship between SES and clinical outcomes (mortality and heart failure events) in
symptomatic RHD patients in Nigeria. The Null hypothesis for research question 1 was
rejected because heart failure events was found to be significantly associated with lower
SES compared with higher SES grouping. In the same vein, I rejected the Null hypothesis
for research question 3 because adherence to BZP partially mediates the effect of SES on
heart failure events in the patients with RHD. However Null hypothesis for research
questions 2 and 4 were not rejected. For research question 2, mortality was not found to
be significantly associated with lower SES compared with higher SES grouping. For
research question 4, adherence to BZP did not significantly mediate the relationship
between SES and mortality.
In the next chapter I will discuss the study results in relation to previous research
related to disparities in clinical outcomes in symptomatic patients with RHD and the use
of benzathine penicillin prophylaxis in the long-term management of these patients.
Limitations and recommendations for future research will be provided along with
implications for social change.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
The purpose of this secondary database analysis study was to assess the
relationship between individual level SES and clinical outcomes (number of heart failure
events and mortality rate) in patients with RHD contained within the Nigerian Registry of
the REMEDY Study. In addition, this study examined how adherence to benzathine
penicillin prophylaxis mediate the effect of socioeconomic status on clinical outcomes
(number of heart failure events and mortality rate) for these patients with RHD. The
health lifestyle theory is an important but underdeveloped area of theoretical discourse
related to medical sociology and public health (Cockerham 2005; 2013). This theory
places emphasis on how structural variables such as socioeconomic status, age, gender,
and race/ethnicity, social networks and living conditions provide the social context for
socialization and experience that ultimately determine lifestyle dispositions and practices
(Cockerham 2005;2013). Poisson regression was used for answering question 1 and
question 3 while logistic regression analysis was used for research questions 2 and 4.
Poisson regression is a generalized linear model form of regression analysis used to
model count data and contingency tables (Field 2015). Poisson regression assumes the
response variable (dependent variable) has a Poisson distribution (Field 2015). It also
assumes the logarithm of the expected value of the response variable can be modelled by
a linear combination of unknown parameters (Field 2015). In contrast logistic regression
is a binary form of classification and represents outcomes that are dichotomous. the
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logistic regression estimates the probability of getting one of the two possible outcomes
(Field 2015)
In this chapter, the discussions will be centered on findings relating to prior
theoretical and empirical literature, theory application, interpretations of findings,
limitations, recommendations, implications for this study, and conclusions.
Research question 1 examined whether the number of heart failure events differ
between RHD patients of low SES and RHD patients of higher SES. When answering
Research Question 1 using the Poison regression model generated, RHD patients from
lower SES group were 4.8 times more likely to develop heart failure events in the two
year follow up period compared with their counterparts in the higher SES group (p=0.04).
This effect was significant at p=0.04 leading to my rejection of the Null hypothesis.
Rejecting the Null hypothesis means that there is enough evidence to say that SES alone
can predict the frequency of heart failure events in these RHD patients. This is to say that
difference in SES groupings have a significant influence on which RHD patient develop
subsequent heart failure events. The findings of an increased risk of heart failure events
in RHD patients from lower SES compared with those from higher SES in this current
study is in tandem with what Zuhlke et al. (2016) reported using country level
socioeconomic groupings rather than individual level SES to assess disparities in heart
failure incidences and mortality among symptomatic RHD patients in Africa, Yemen and
India (Zuhlke et al., 2016). It is also in tandem with the findings of Burch et al., (2016)
who studied the effect of SES on viral suppression among HIV infected individuals and
reported that low SES significantly predict viral non suppression (adjusted hazard ratio
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[HR] for greatest financial hardship vs none 2·3, 95% CI 1·4–3·9; non-employment 3·0,
2·1–4·2; unstable housing vs home-owner 3·3, 1·8–6·1; non-university education 1·6,
1·1–2·3 ) (Burch et al., 2016). While clinical outcomes for chronic diseases are hinged
more on behavior and social support in the community, a person’s SES group may define
their company, the type of community they live in and also by extension their code of
conduct and possibly health seeking behavior (Cockerham et al., 2017). Unlike HIV
where family and peer support exist to assist and improve patient adherence to therapy,
RHD is a neglected disease of poverty usually associated with abandonment and poor
access to care (Cockerham et al., 2017). Lower SES as seen here is usually associated
with low purchasing power (Cockerham et al., 2017). In situations where health
expenditure is majorly out of pocket as subsist in Nigeria, treatment cost may be
prohibitively high leading to non-adherence to drug therapy and hence recurrent heart
failure events as seen among these RHD patients from lower SES group (Cockerham et
al., 2017). Other factors inherent in the community like social capital available,
healthcare access may also play important role in addition to SES in determining
outcome for patients with RHD and thus provide avenues for future research (Cockerham
et al., 2017).
The fact that those in lower SES were about 4.8 times more likely to develop
heart failure events is of clinical relevance in the management of patients with RHD from
lower SES household (Cockerham et al., 2017). SES determines purchasing power in
Nigeria and by extension access to healthcare (Uzochukwu et al., 2015). Lower SES is
associated with low purchasing power and by extension inability to pay for healthcare
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services especially when the payment is out-of-pocket (Uzochukwu et al., 2015). The
implication for these patients is possible increased exposure to recurrent heart failure and
its attendant consequences as a result of inability to pay for healthcare services thus
affecting outcome for them (Cockerham et al., 2017; Uzochukwu et al., 2015; Zuhlke et
al., 2016).
Research Question 3 examined whether there is a significant difference in number
of heart failure events between RHD patients of low SES and RHD patients of higher
SES when adjusting for the effect of benzathine penicillin prophylaxis adherence. In
answering research question 3 Poisson regression model was used to assess the potential
mediatory role of adherence to BZP prophylaxis in the relationship between SES and
number of heart failure events in these RHD patients. The results of the Poisson
regression analysis showed that the odds of developing heart failure event were
approximately 4.8 times more likely for patients of lower SES group compared to RHD
patients in the higher SES group when excluding adherence to BZP prophylaxis but
holding disease severity and age group of participant constant. (OR = 4.77, 95% CI [1.07,
21.32]). Similarly, being an RHD patients with poor adherence to BZP prophylaxis was
associated with a 58% likelihood of developing a heart failure event compared with those
RHD patients from higher SES (OR = 0.42, 95% CI [0.12, 1.45], p = 0.21). When finally,
BZP adherence was added to the model with SES as predictors of heart failure events,
SES remain significant as a predictor of heart failure events even though the odds
reduced to 4.6 while BZP adherence was non-significant in predicting heart failure event.
This thus means that BZP adherence partially mediates the relationship between SES and
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heart failure leading to my rejection of the Null hypothesis (Field, 2015). Adherence to
BZP has been shown to be an important determinant of heart failure recurrences in
patients with RHD (Watkins et al., 2017; Zuhlke et al., 2016). My findings here are in
tandem with what Okello reported among Ugandan children with RHD where increased
incidence of heart failure was seen in children who had poor adherence to BZP
prophylaxis (Okello et al., 2017). However, the fact that the result showed partial
mediation suggest that some other variables apart from BZP adherence might be
influencing the odds of heart failure in these patients with RHD. Adult age which was
associated with a significant increased risk of heart failure events in a separate model
assessing confounders maybe one of such variables acting alongside BZP adherence to
influence the relationship between SES and heart failure events (Watkins et al., 2017).
Adult age may be a proxy for the duration lived with the disease especially since the
disease usually begins in childhood (Gitura 2016; Okello et al., 2017; Watkins et al.,
2017). Research has shown that RHD disease profile and outcomes worsened as the
patient gets older (Gitura 2016; Okello et al., 2017). This is important in the sense that
such persons would have lived longer with the disease especially seeing that the disease
commonly starts in mid childhood (Claussen, 2015; Cockerham et al., 2017; Zühlke et
al., 2015). In addition, being older increases the chances of having a more severe disease
in addition to developing other complications such as arrhythmias and infective
endocarditis all of which increases the risk of recurrent heart failure (Claussen, 2015;
Cockerham et al., 2017; Zühlke et al., 2015). It is thus not surprising to find increased
number of heart failure events, a usual complication of RHD in those older than 18 years
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(Gitura 2016; Okello et al., 2017). While BZP adherence has been demonstrated to
improve clinical outcomes especially heart failure and ARF, this is however only useful
early on in the disease before permanent geometric changes occur in the heart (Gitura
2016; Okello et al., 2017). Therefore, our findings of partial mediatory influence of BZP
prophylaxis in this cohort of mixed population of adult and children may point to the
need to disaggregate future study by age groups (Gitura 2016; Okello et al., 2017;
Watkins et al., 2017). This was why person year of follow up was also added as an offset
variable in the model (Field 2015). Therefore, while SES alone may be one factor that
significantly predispose to heart failure in RHD patients studied in Nigeria, however,
when SES is combined with the age of the patient, disease severity and years of followup, it may become an even more important determining factor for the possible risk of
heart failure in patients with RHD as shown in this study (Claussen, 2015; Cockerham et
al., 2017; Zühlke et al., 2015).
Research Question 2 examined whether the risk of mortality differ between RHD
patients of low SES and RHD patients of higher SES. When answering research question
2 using simple logistic regression model, RHD patients from lower SES group were
about 42% less likely to die in the two year follow up period compared with their
counterparts in the higher SES group (OR=0.58, 95% CI=0.26 -1.29, p = 0.18). Because
this was not statistically significant at p = 0.05, the Null hypothesis was not rejected.
Failing to reject the Null hypothesis means that there is not enough evidence to say that
SES alone can predict mortality in these RHD patients (Field, 2013). In other words, the
difference in SES groupings have no significant influence on the risk of death among
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these cohort of RHD patient (Field 2013). While data is lacking for all-cause mortality by
socioeconomic quintiles for patients with RHD, Zuhlke et al., (2016) in the REMEDY
study had evaluated 3343 RHD patients across 14 developing countries (Zuhlke et al.,
2016). They reported a median age at death of 28 years. Similar to my findings in the
current study, Zuhlke et al., also reported a significant increase in mortality with
increasing age, with adults having a 50% higher risk of death than those <18 years of age
(HR, 1.50; 95% CI, 1.11–1.95) (Zuhlke et al., 2016). Even though individual level SES
was not assessed in their study, most of the deaths they reported was found in patients
from low-income countries (21%) compared with those from middle-income countries
(12% to 17%) (Zuhlke et al., 2016). The association of higher SES with increased risk of
death in my study, though not significantly so raises important questions for management
of patients with RHD. While lower socioeconomic status has been associated with an
increased risk of death in patients with stroke and ischaemic heart disease, the finding of
the reverse here needs further studies for clarification (Psaltopoulou et al., 2017).
Research question 4 examined whether there is a significant difference in risk of
mortality between RHD patients of low SES and RHD patients of higher SES when
adjusting for the effect of benzathine penicillin prophylaxis adherence. In answering
research question 4 multivariable logistic regression model was used to assess the
potential mediatory role of adherence to BZP prophylaxis in the relationship between
SES and risk of mortality in these RHD patients. In this logistic regression analysis, the
odds of dying were approximately 49% less likely for patients of lower SES group
compared to RHD patients in the higher SES group when adherence to BZP was
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excluded in the model but holding disease severity and adherence to BZP prophylaxis
constant. (OR=0.51; 95% CI 0.04- 7.03). However, when adherence to BZP prophylaxis
was included in the model, the odds of dying in RHD patients from lower SES group was
48.8% lower compared with RHD patients from higher SES group (OR=0.51, 95% CI
=0.04 -7.03). In addition, the odds of dying for those RHD patients with poor adherence
(<80% total expected dose of BZP per year) was about 3.3 time more compared with
those RHD patients with good adherence (>80% of total expected dose of BZP per year)
albeit not statistically significant (OR=3.2 8, 95% CI=0.42-25.78, p= 0.26). Our finding
is similar to the report by Okello et al. (2017) where Ugandan RHD patients with poor
BZP adherence had significantly greater mortality (31% vs. 9%, log rank p < 0.001) and
also significantly higher risk of death compared with those with good adherence
(HR = 3.81, CI 1.92–7.63, p = 0.001) (Okello et al., 2017). Death in those with poor
adherence was also significantly associated with heart failure (HR 8.36, CI 3.28–21.31,
p = 0.001) (Okello et al., 2017).
Thus, SES alone unlike the model for heart failure events is inadequate in
explaining the risk of dying in patients with RHD. However, when other factors like
disease severity, the age of the patient and also the duration of follow up are considered
in the model, SES may have a significantly important determining factor for the possible
risk of dying in patients with RHD. The longer an RHD patient lives with the chronic
disease, the more likely other complications like stroke and arrhythmias set in and
thereby increasing the risk of dying. Older patients as seen in this study would have lived
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longer with the disease especially seeing that the disease commonly starts in mid
childhood.
Impact of Key Variables on Multiple Outcomes in RHD
RHD is a chronic disease associated with multiple outcomes (Cannon et a., 2017;
Chamberlain-Salaun et al., 2016; Zuhlke et al., 2016). Several key variables like disease
severity at diagnosis, left ventricular end diastolic dimension, presence of arrhythmias,
adherence to drug therapy and presence of complications such as endocarditis, stroke and
acute rheumatic fever will have a significant impact on the eventual outcome of the
patient (Watkins et al., 2017). Cannon et al., (2017) using a disease register had reported
that a diagnosis of severe RHD especially in young persons is associated with a 10%
chance of dead within 6 years of diagnosis (Cannon et al., 2017). They further reported
that patients diagnosed with moderate RHD had a mixed prognosis 10 years after
diagnosis with roughly one third progressing to severe RHD (with or without surgery),
one third remained moderate, and one third regressing to mild RHD (Cannon et al.,
2017). Those who had mild RHD at diagnosis had the most favorable prognosis, with
over 60% remaining mild after 10 years, and 10% being inactive by the end of the 14‐
year study period (Cannon et al., 2017).
RHD being a disease of poverty and social disadvantage is associated with poor
access to healthcare with consequent increase episodes of unrecognized acute rheumatic
heart fever (ARF) ( Watkins et al., 2017). Recurrent ARF episodes cause severe damage
to the valve structure as well as also predisposing the patients to dilatation of heart
chambers and other severe consequences (Cannon et a., 2017; Chamberlain-Salaun et al.,

88
2016; Zuhlke et al., 2016). BZP secondary prophylaxis is used to prevent such
recurrences and hence improve outcomes in RHD patients (Cannon et a., 2017;
Chamberlain-Salaun et al., 2016; Zuhlke et al., 2016). Furthermore, there was no
significant association of poor adherence to BZP prophylaxis with the occurrence of heart
failure events in our study. However, I found adherence to BZP to partially mediate the
influence of SES on heart failure events confirming what has been reported in the
literature (Cannon et a., 2017; Chamberlain-Salaun et al., 2016; Zuhlke et al., 2016).Such
effect of BZP prophylaxis is thought to be greatest in early stages of the disease (Cannon
et a., 2017; Chamberlain-Salaun et al., 2016; Zuhlke et al., 2016). Our patients like many
others in developing countries access medical care late when their disease is severe with
associated substantial valve damage from unrecognized recurrent rheumatic fever
episodes at which point the hemodynamic consequences of severe valve disease may be
the overwhelming determinants of prognosis (Cannon et a., 2017; Chamberlain-Salaun et
al., 2016; Zuhlke et al., 2016). It is thus not surprising that adherence to BZP prophylaxis
did not significantly affect the clinical outcome (Heart failure and death) in Nigerian
patients with RHD (Cannon et a., 2017; Chamberlain-Salaun et al., 2016; Zuhlke et al.,
2016).
Even though RHD begins in childhood, its highest burden is seen in adolescents
and young adults living in poverty and social disadvantage (Cannon et a., 2017;
Chamberlain-Salaun et al., 2016; Zuhlke et al., 2016). Disease severity at diagnosis and
the degree of adherence to benzathine penicillin prophylaxis are the most important risk
factors to heart failure recurrence in RHD patients (Cannon et a., 2017; Chamberlain-
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Salaun et al., 2016; Zuhlke et al., 2016). Complications such as heart failure and death are
usually associated with severe disease at diagnosis, poor access to BZP prophylaxis as
well as poor adherence to BZP prophylaxis when available (Chamberlain-Salaun et al.,
2016; Zuhlke et al., 2016). Together with recurrent heart failure, these factors contribute
to the increased mortality rates seen in people with RHD (Cannon et a., 2017; Zuhlke et
al., 2016). Low SES which is the surrogate for poverty affects access to care, BZP
prophylaxis and other treatments for complications like heart failure thereby increasing
the risk of dying in such patients (Cannon et a., 2017; Chamberlain-Salaun et al., 2016;
Zuhlke et al., 2016).
Interpretation of Findings
This study and others on RHD patients contained within the REMEDY global
registry adds to the findings of the relationship between SES and the significant increases
in number of heart failure events (Zuhlke et al. 2014; Zuhlke et al., 2016). Similarly, it
also adds to the findings on the relationship of SES and risk of mortality in symptomatic
RHD patients contained within the REMEDY global registry (Zuhlke et al., 2014; 2016).
The Health lifestyle theory used in this study offered an opportunity for
understanding how class circumstance (socioeconomic status) influences patients’
choices and decision (agency) on adhering to the monthly penicillin injection
(adherence), a health behavior necessary for improving the clinical outcome for these
symptomatic patients with RHD (Cockerham 2005;2013).
An increased risk of heart failure among patients from lower SES was observed in
my study similar to what was reported by Zuhlke et al., in the REMEDY study though
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Zuhlke et al., used country level SES classification by the World Bank in grouping the
patients (Zuhlke et al., 2016). Lower SES is associated with worsening clinical outcomes
in chronic disease such as RHD (Baro et al., 2018). Our finding is also similar to what
Potter et al., (2019) reported in a review of the literature where they showed a significant
association between incident heart failure with SES households (Potter et al., 2019).
Potter reported that patients from low SES households have a 1.62 times risk of heart
failure compared with those from higher SES households (HR 1.62, 95% CI 1.50-1.76)
(Potter et al., 2019). Furthermore, my study observed adherence to BZP prophylaxis in
patients with RHD only partially mediate the relationship between SES and frequent
heart failure events. Okello et al., had demonstrated a reduced incidence of heart failure
among Ugandan RHD patients with good adherence to BZP (Okello et al., 2017). Even
though my study did show a partial influence of BZP adherence on heart failure events,
however, the fact that other researchers too have shown an association between poor
adherence to BZP prophylaxis and increased risk of heart failure events calls for a closer
follow up of RHD patients with lower SES in order to help reduce the frequency of heart
failure events and thus improve their outcomes (Cannon et a., 2017; Watkins et al.,
2017).
A reduced risk of death among patients from low SES, though not statistically
significant, was also found in this study in contrast to what Okello et al., reported among
RHD patients in Uganda (Okello et al., 2017). Furthermore, this study also found poor
adherence to benzathine penicillin prophylaxis to be associated with an increased risk of
mortality though this did not reach statistical significance. This lack of significance may

91
be related to the mixed population of children and adults used in this study (Cannon et a.,
2017; Chamberlain-Salaun et al., 2016; Zuhlke et al., 2016). Children being products of a
household SES are a different population from adults. It will thus be advisable that future
study should try to separate the two groups and assess their effects separately (Cannon et
a., 2017; Chamberlain-Salaun et al., 2016; Zuhlke et al., 2016).
Limitations of the Study
This study was based on secondary data analysis of data contained within the
Nigerian site of the REMEDY study. The sample in this study consisted of symptomatic
RHD patients presenting for care in a hospital emergency room, ward or clinic and may
not be representative of all RHD patients in those localities and thus may limit
generalizability of the results of the study to all populations of patients with RHD. As for
the sampled population, the use of a mixed population consisting of both children and
adults with RHD in the study might introduce some complexities in the effect of SES on
the studied outcomes. SES for an adult is a direct reflection of the person’s social
standing, economic class and ability to access and possibly pay for services especially
health services in Nigeria which is mainly out of pocket expense. However, for a child,
the SES classification used was the parental SES classification. Even though this was
done because child care is a responsibility of the parents and care givers, it may however
over estimate or under estimate the effect of SES especially since parental care is not so
much dependent on SES but culture in Africa (Amzat & Razum 2018). However, in
future, children should be separated from adults and if possible, compared on the key
outcomes variables so as to be able to make appropriate age specific conclusions seeing
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that the disease characteristics may differ between children and adults. Other variables
such as duration lived with the diseases, frequency of hospitalization and total household
income all factors that have been shown to significantly impact outcome in chronic
disease management could have been assessed if available in the data set. But this was
not possible because of their unavailability in the dataset.
Implications for Social Change
Rheumatic heart disease (RHD) has continued to significantly contribute to
morbidity and mortality among children and adolescents in resource constraint
communities especially in sub Saharan Africa where poverty and poor hygiene continues
to plague the vast majority of the population (Marijon et al., 2012; Zühlke & Steer 2013)
It is important to assess how SES, age category and adherence to BZP impacts on
clinical outcomes for chronic diseases such as rheumatic heart diseases especially in
developing countries where health expenditure is mainly out of pocket expenses
(Remond et al., 2016; Yacoub et al., 2016; Zühlke et al., 2016). Understanding the
mechanism through which SES and adherence to BZP prophylaxis affects these health
outcomes represent potentially modifiable targets for intervention to improve health
outcomes not just for patients with RHD but also for patients with other chronic diseases
(Remond et al., 2016; Yacoub et al., 2016; Zühlke et al., 2016).
In this study, risk for developing heart failure events was higher for RHD patients
in low SES group compared with those in higher SES group. Finding a significantly
higher number of heart failure events in patients from low SES in this study points to the
need to pay close attention to the management of these group of patients with RHD
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especially as it relates to counseling on those factors that may predispose to the frequent
recurrence of heart failure (Classen 2015; Cockerham et ail., 2017). Thus, physicians,
cardiologists and nurses who care for these patients will need to do more in counseling
about drug adherence especially adherence to diuretics for heart failure and also
benzathine penicillin for prevention of recurrent rheumatic fever, an important cause of
heart failure in RHD patients (Gonzalez et al., 2016). In addition, health policy will need
to focus on reducing barriers to care for people in the low SES groupings of the society as
well as reducing out of pocket expense to health care by making health insurance and
social services universally accessible. This will help improve clinical outcomes for
patients with RHD and other chronic diseases.
Recommendations
This secondary analysis study was conducted on de-identified data sets of
symptomatic RHD patients in Nigeria collected using case record forms by cardiologists
working in multiple hospitals sites from January 2010 to January 2014. The major
limitation of this study of being a secondary data analysis is acknowledged. However,
larger prospective longitudinal studies utilizing multiple sites in Nigeria are needed to
confirm the findings of this study.
Previous studies had utilized a mixed population consisting of children and adults
just as was done in this study. Future researchers should focus on disaggregating the
children data from the adult data in order to make definitive statements about SES and its
effects on clinical outcomes such as heart failure and mortality in patients with RHD.
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SES grouping utilized proxies such as educational attainment and occupation
rather than actual income earned by the patients (or parents of children). Since care in
Nigeria is mainly out of pocket expenses, it is important that future researchers try to
assess actual income or earnings of the patients as a measure of SES. In addition, a
prospective cohort design would be most appropriate for such future research.
Recommendation for practice as a result of this study includes the need for
increased surveillance and monitoring for adherence to management in patients with
RHD from social disadvantaged backgrounds in order to improve their clinical outcomes.
Conclusions
RHD is a disease of social disadvantage associated with poverty, malnutrition,
poor hygiene and sanitation, overcrowding and poor access to health. The persistence of
these poverty defining problems in Nigeria and most parts of sub Saharan Africa is what
is currently responsible for the persistence of RHD as well as the deaths occurring from
the complications of the disease.
The results of this study showed that after controlling for age, disease severity at
baseline and adherence to BZP, symptomatic RHD patients from the Nigerian sites of the
REMEDY study who are from low SES group have a higher incidence heart failure rates
compared with their counterparts from a higher SES group. Poor adherence to BZP
prophylaxis did show partial mediation of the relationship between SES and number of
heart failure events or but not mortality. Furthermore, lower SES was significantly
associated with increased risk for developing heart failure events. These findings suggest
that socioeconomic gradient is an important predictor of clinical outcomes (heart failure
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events) among symptomatic RHD patients seen in Nigeria. Paying attention to
socioeconomic status of a patient can be an important tool for improving clinical
outcomes for these patients. Future research should examine the effect of socioeconomic
status and clinical outcomes for patients with RHD separately for children and adults.
This will help bring about results that can be used for targeted actions and policy
formulation and implementation appropriate for each age group.
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